Current or prior use of immunosuppressive medication within 14 days before the first dose of their assigned IP; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent \r\n* Steroids as pre-medication for hypersensitivity reactions (e.g., CT scan pre-medication)Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and systemic mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXParticipants should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 2 weeks of study drug administration; these drugs may interfere with the activity of ipilimumab and nivolumab if administered at the time of the first ipilimumab dose; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; participants are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if >= 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted; use of anabolic steroids is permittedXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 6 weeks prior to cycle 1 day 1;\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXPatients requiring daily systemic corticosteroids are not eligible; patients must not have received systemic corticosteroids within 7 days prior to enrollment; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid; Note: use of topical or inhaled corticosteroids will not render a patient ineligibleXx_NEWLINE_xXHas received more than 2 days of systemic corticosteroids for aGVHD.Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti?tumor necrosis factor agents) within 2 weeks prior to randomization or anticipated need for systemic immunosuppressive medications during the studyXx_NEWLINE_xXPatients on any systemic corticosteroid therapy within one week before the planned date for first dose on study would not be eligible; exception: patients on physiologic replacement doses of corticosteroids are permittedXx_NEWLINE_xXAny condition that would prohibit administration of corticosteroidsXx_NEWLINE_xXSubjects who are on systemic corticosteroids (intravenous (IV) or oral steroids, excluding inhaled, topical or ophthalmic corticosteroids), or anti-epileptic drugs for treated brain metastasisXx_NEWLINE_xXNo chronic (>= 1 month) use of oral steroids at the time of study enrollment; inhaled or topical steroids are acceptableXx_NEWLINE_xXPatients must not have an organ allograft or other history of immune compromise; patients must not be receiving chronic, systemic treatment with corticosteroids or other immunosuppressive agent; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXPatients must have discontinued steroids >= 1 week prior to registration to Step 0 and remain off steroids thereafter, except as permitted (see below); patients with glioblastoma (GBM) must have been on stable dose of steroids, or be off steroids, for one week prior to registration to treatment (Step 1, 3, 5, 7)\r\n* NOTE: The following steroids are permitted (low dose steroid use is defined as prednisone 10 mg daily or less, or bioequivalent dose of other corticosteroid):\r\n** Temporary steroid use for computed tomography (CT) imaging in setting of contrast allergy\r\n** Low dose steroid use for appetite\r\n** Chronic inhaled steroid use\r\n** Steroid injections for joint disease\r\n** Stable dose of replacement steroid for adrenal insufficiency or low doses for non-malignant disease\r\n** Topical steroid\r\n** Steroids required to manage toxicity related to study treatment, as described in the subprotocols\r\n** Steroids required as pre- or post-chemotherapy medication for acceptable intervening chemotherapy\r\n*** NOTE: Steroids must be completed alongside last dose of chemotherapyXx_NEWLINE_xXConditions that would prohibit administration of corticosteroidsXx_NEWLINE_xXPatients must not have received any immunosuppressive medication within 28 days prior to sub-study registration and must not be planning to receive these medications while on protocol therapy; systemic corticosteroids must be stopped at least 24 hours prior to sub-study registration; however, intranasal and inhaled corticosteroids are allowed at any time before and during protocol therapyXx_NEWLINE_xXPatients must not have a condition requiring systemic corticosteroids equivalent to > 10 mg prednisone per day or other immunosuppressive medications within 2 weeks of randomization; inhaled, intra-articular, and epidural steroids are permissibleXx_NEWLINE_xXNo systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of registrationXx_NEWLINE_xXNo systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of re-registrationXx_NEWLINE_xXNo patients that have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXNo systemic daily treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days of registrationXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea or steroids as computed tomography [CT] scan contrast premedication) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXNO patients receiving systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drugXx_NEWLINE_xXPatients receiving chronic pharmacologic doses of corticosteroids are not eligible; for the purposes of eligibility, chronic exposure is defined as anticipated exposure of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned exposure) must still meet the normal blood glucose requirement; patients receiving chronic inhaled corticosteroids or chronic physiologic replacement doses of corticosteroids are eligibleXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization; however,\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea; or chronic daily treatment with corticosteroids with a dose of =< 10 mg/day methylprednisolone equivalent) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXNo ongoing condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications; no treatment with other immunosuppressive agents within 14 days prior to the first dose of study drug; topical, ocular, intra-articular, intranasal, inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.; a brief (less than 3 weeks) course of corticosteroids (any amount) for prophylaxis (for example: contrast dye allergy) or for treatment of non-autoimmune conditions (for example: delayed-type hypersensitivity reaction caused by a contact allergen) is permitted if > 14 days since last doseXx_NEWLINE_xXPatients who received systemic corticosteroids within 28 days of enrollment on this protocol, except as specified, are not eligibleXx_NEWLINE_xXPatients must not have received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 4 weeks prior to cycle 1, day 1; exceptions: (1) patients may have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea); (2) the use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) is allowed, provided the following is met: minimum of 2 weeks prior to cycle 1, day 1; patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled; the use of corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids within < 2 weeks prior to treatment start, or who have not fully recovered from side effects of such treatment\r\n* The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXPatients requiring chronic treatment with systemic steroid therapy, other than replacement-dose steroids in the setting of adrenal insufficiency. Topical, inhaled, nasal and ophthalmic steroids are not prohibited.Xx_NEWLINE_xXPatients receiving systemic treatment with any immunosuppressive medication (other than steroids as described above).Xx_NEWLINE_xXCurrently receiving systemic corticosteroids or other immunosuppressive medications or has a medical condition that requires the chronic use of corticosteroids; Note: inhaled and topical steroids are permittedXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first dose of study drug. Inhaled or topical steroids, and adrenal replacement steroid doses are permitted in the absence of active autoimmune disease.Xx_NEWLINE_xX5. Current use or prior use of immunosuppressive medication within 4 weeks prior to first dose of TAB001, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids not to exceed 10mg/day of prednisone or equivalent;Xx_NEWLINE_xXParticipants requiring chronic treatment with systemic steroid therapy, other than replacement-dose steroids in the setting of adrenal insufficiency; topical, inhaled, nasal and ophthalmic steroids are allowedXx_NEWLINE_xXParticipants receiving systemic treatment with any immunosuppressive medication (other than steroids as described above)Xx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy (excludes inhaled corticosteroids) within 7 days of first dose of study drugXx_NEWLINE_xXHas received systemic immunosuppressive treatments, aside from systemic corticosteroids within three months of start of study drugXx_NEWLINE_xXUse of any systemic immunosuppressive treatments including corticosteroids, cyclosporine, mycophenolate mofetil et cetera, ongoing or within the last 3 months prior to day 1 of treatment\r\n* (NOTE: Patients on physiologic dose of corticosteroids [=< 10 mg/day of prednisone or equivalent] for long-term hormone-replacement therapy or those requiring short, intermittent courses of corticosteroids for hypersensitivity prophylaxis [such as for iodinated computed tomography (CT) contrast prophylaxis] or those using intranasal, inhaled, topical steroids, or local steroid injection [e.g., intra-articular injection] can be allowed)Xx_NEWLINE_xXCurrently receiving or has received systemic corticosteroids (=< 14 days prior to registration, or who have not fully recovered from side effects of such treatment); NOTE: The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXTreatment with systemic immune modulators including, but not limited to, non-topical systemic corticosteroids, cyclosporine, and tacrolimus within 2 weeks before enrollment (day 1).Xx_NEWLINE_xXPrior or current systemic immunosuppressive therapy (> 10 mg/day prednisone equivalents) within 7 days prior to C1D1 of study therapy; inhaled, ocular, intra-articular, intranasal, and topical corticosteroids are permitted in absence of active autoimmune disease\r\n* Adrenal replacement doses are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients receiving systemic corticosteroids (patients off steroids for at least 48 hours are eligible)Xx_NEWLINE_xXTreatment with systemic immunosuppressive medicationsXx_NEWLINE_xXCorticosteroids or any other immunosuppressive therapy -2 weeks NOTE: Use of inhaled or topical steroids is not an exclusionXx_NEWLINE_xXUse of systemic corticosteroids or other systemic immunosuppressive drugsXx_NEWLINE_xXPatients must not be receiving chronic systemic corticosteroids at doses greater than physiologic dosing (inhaled corticosteroids acceptable).Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of study therapy with the exceptions of intranasal corticosteroids or systemic corticosteroids at physiological doses that do not exceed 10mg/day of prednisone or an equivalent corticosteroid.Xx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; subjects are permitted to use topical, ocular, intraarticular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXStable dose of corticosteroids for at least 7 daysXx_NEWLINE_xXHas received systemic immunosuppressive treatments, aside from systemic corticosteroids, within three months of start of study drugXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea, premedication for a radiologic contrast allergy) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed\r\n* Patients who receive low-dose supplemental corticosteroids for adrenocortical insufficiency are allowedXx_NEWLINE_xXAre receiving increasing doses of corticosteroidsXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 2 weeks of the study drug administration. Note: Adrenal replacement doses ? 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted.Xx_NEWLINE_xXParticipants who are currently receiving or have received systemic corticosteroids =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment; the following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXOther medications (meds:)\r\n* Participants who are receiving any other investigational agents\r\n* Immunosuppressive medications / steroids\r\n** Subject must not require high dose systemic corticosteroids defined as dexamethasone > 4 mg/day or bioequivalent for at least 3 consecutive days within 2 weeks prior to day 1 of study therapy\r\n** Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease\r\n** Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption)\r\n** Physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents\r\n** A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXKnown history or evidence of significant immunodeficiency due to underlying illness (e.g. human immunodeficiency virus [HIV]/acquired immunodeficiency syndrome [AIDS]) and/or medication (e.g. systemic corticosteroids or other immunosuppressive medications, including cyclosporine, azathioprine, interferons in the 4 weeks before the first dose of study treatment). Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisolone equivalent) or other immunosuppressive medications within 14 days of the first dose of study treatment. Inhaled or topical steroids and adrenal replacement steroid doses are permitted in the absence of autoimmune diseaseXx_NEWLINE_xXConcurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids except inhaled or intranasal corticosteroids (with minimal systemic absorption)Xx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent, except corticosteroids with a daily dosage equivalent to prednisone =< 20 mg; however, patients receiving corticosteroids must have been on a stable dosage regimen for a minimum of 4 weeks prior to the first treatment with everolimus; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXThe following uses of corticosteroids are permitted: single doses, topical applications (e.g.: for rash), inhaled sprays (e.g.: for obstructive airways diseases), eye drops or local injections (e.g.: intra-articular)Xx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug at a dose greater than the equivalent of 10 mg prednisone/day, or who have not fully recovered from the side effects of such treatment; the following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXOngoing immunosuppressive therapy including systemic corticosteroids (prednisone or equivalent =< 10 mg daily allowed as clinically warranted); patients are allowed to use topical or inhaled corticosteroidsXx_NEWLINE_xXAny condition requiring concurrent systemic immunosuppressive therapyXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive therapyXx_NEWLINE_xXConcomitant use of medications known to have strong inhibition or induction of CYP3A enzymes is discouraged and should be discussed with the study principal investigator (PI); note that systemic corticosteroids (e.g., dexamethasone is a CYP3A inducer) are not allowed; inhaled corticosteroids are allowedXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agentsXx_NEWLINE_xXPatients must have no clinical evidence of leptomeningeal or brain metastasis causing spinal cord compression that are symptomatic or untreated or not stable for >= 3 months (must be documented by imaging) or requiring corticosteroids; subjects on a stable dose of corticosteroids > 1 month or who have been off of corticosteroids for at least 2 weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP) medical monitor; subjects must also be off of enzyme-inducing anticonvulsants for > 4 weeksXx_NEWLINE_xXTREATMENT: Patients receiving systemic corticosteroidsXx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary; topical or inhaled steroids are allowedXx_NEWLINE_xXPatients who have concurrent conditions resulting in immune compromise, including chronic treatment with corticosteroids or other immunosuppressive agentsXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXHas any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug (except that inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response are permitted).Xx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; however, systemic corticosteroids may be indicated after starting the study drugs to treat immune-related adverse reactions; inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXTreatment with high dose systemic corticosteroids defined as dexamethasone > 2mg/day or bioequivalent within 7 days of initiating therapyXx_NEWLINE_xXChronic systemic therapy with immunosuppressive agents including corticosteroids.Xx_NEWLINE_xXHave chronic daily treatment with corticosteroids, excluding inhaled or topical steroids.Xx_NEWLINE_xXParticipants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administrationXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPHASE II EXCLUSION CRITERIA: Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti?tumor necrosis [anti-TNF] factor agents) within 14 days prior to randomization or anticipation of need for systemic immunosuppressive medications during the study.Xx_NEWLINE_xXThe use of immunosuppressive medication within 28 days prior to the first dose of nivolumab; the following are exceptions to this criterion:\r\n* Intranasal, topical, inhaled corticosteroids or local steroid injections (e.g. intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication)Xx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients with long-term glucocorticosteroid use; the following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXParticipant is currently receiving or has received systemic corticosteroids ?2 weeks prior to starting study drug, or has not fully recovered from side effects of such treatment. Note: The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops, or local injections (e.g., intra-articular).Xx_NEWLINE_xXPatients must have previously untreated disease (except for one week or less of corticosteroids)Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medications during the studyXx_NEWLINE_xXPatients should be excluded if they have a condition requiring chronic systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients with contrast allergies who can tolerate contrast with corticosteroid premedication are not excludedXx_NEWLINE_xXReceived corticosteroids within the past 1 weekXx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment\r\n* The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXUse of escalating or chronic supraphysiologic doses of corticosteroids or immunosuppressive agents (such as, cyclosporine). [Use of topical, ophthalmic, inhaled, and intranasal corticosteroids permitted].Xx_NEWLINE_xXPatients receiving systemic corticosteroids (patients off steroids for at least 48 hours are eligible)Xx_NEWLINE_xXSubjects currently receiving systemic corticosteroids above 10 mg daily of prednisone or equivalent for more than 14 days; subjects receiving other systemic immunosuppressive drugs greater than 10 mg prednisone or equivalent for more than 14 days; exceptions include: inhaled, intranasal, ophthalmic, and topical corticosteroids, local corticosteroid injections (e.g., intra-articular injections), and subjects requiring corticosteroid pre-medication for hypersensitivity reactions (e.g. computed tomography [CT] scan pre-medication)Xx_NEWLINE_xXSubjects with medical conditions that require the chronic use of systemic corticosteroids; exceptions include: inhaled, intranasal, ophthalmic, and topical corticosteroids, local corticosteroid injections (e.g., intra-articular injections), and subjects requiring corticosteroid pre-medication for hypersensitivity reactions (e.g. CT scan premedication)Xx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment\r\n* The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXConcurrent use of high dose of systemic steroids. The use of inhaled, topical and ophthalmic steroids is allowed.Xx_NEWLINE_xXConcurrent medical condition requiring the use of immunosuppressive medications, or systemic or topical corticosteroids; systemic or topical corticosteroids must be discontinued at least 4 weeks prior to enrollment. Inhaled or intranasal corticosteroids (with minimal systemic absorption may be continued if the subject is on a stable dose). Non-absorbed intra-articular steroid injections will be permitted; or use of other investigational drugs (drugs not marketed for any indication) within 30 days prior to study drug administration. Use of steroids as prophylactic treatment for subjects with contrast allergies to diagnostic imaging contrast dyes will be permitted;Xx_NEWLINE_xXPatient has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first dose; inhaled or topical steroids and adrenal replacement steroid doses are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients receiving systemic corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of systemic corticosteroid; Note: patients who are using topical or inhaled corticosteroids are eligibleXx_NEWLINE_xXTreatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the studyXx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; Note: Patients who are currently using inhaled, intranasal, ocular, topical or other non-oral or non-IV steroids are not necessarily excluded from the study but need to be discussed with the study chairXx_NEWLINE_xXPatients that transition from active aGvHD to cGvHD without tapering off corticosteroids ± CNI and any systemic treatment * Patients receiving up to 30 mg by mouth once a day of hydrocortisone (i.e., physiologic replacement dose) of corticosteroids are allowed.Xx_NEWLINE_xXNo escalation of systemic immunosuppression in terms of increase of corticosteroids or addition of new agent / modality within 2 weeks of randomization. (Note that increasing calcineurin inhibitors or sirolimus to achieve therapeutic trough levels is allowed.) Topical skin and topical gastrointestinal steroids are allowed.Xx_NEWLINE_xXPatients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of the study drugs.Xx_NEWLINE_xXConcurrent systemic therapy with immunosuppressive agents; use of hormonal agents within 7 days before the start of trial treatment. Note: subjects receiving bisphosphonate or denosumab are eligible provided treatment was initiated at least 14 days before the first dose of avelumab. Subjects receiving immunosuppressive agents (such as corticosteroids) for any reason should be tapered off these drugs before initiation of the study treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement dose, equivalent to ? 10 mg prednisone daily). Steroids with no or minimal systemic effect (topical, inhalation) are allowed.Xx_NEWLINE_xXOngoing immunosuppressive therapy, including systemic or enteric corticosteroidsXx_NEWLINE_xXPatients receiving systemic chronic steroid therapy or any immunosuppressive therapy (? 10mg/day prednisone or equivalent). Topical, inhaled, nasal and ophthalmic steroids are allowed.Xx_NEWLINE_xXThe use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXPatients who require systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXChronic, systemic treatment with immunosuppressive agents; patients who require a stable dose of corticosteroids for control of cerebral edema are eligible; topical or inhaled steroids are also allowedXx_NEWLINE_xXNo history of long-term use of corticosteroids or concurrent short term use of corticosteroids is allowedXx_NEWLINE_xXIs on chronic systemic steroids.Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXPatients receiving unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms other than CNS related, dose must have been stabilized (or decreasing) for at least 5 days before first dose of INC280Xx_NEWLINE_xXAre currently receiving or have had prior use of immunosuppressive medication within 28 days before the first dose of study drug, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 milligrams/day of prednisone, or an equivalent corticosteroid.Xx_NEWLINE_xX?7 days for immune-suppressive-based treatment for any reason. Note: Use of inhaled or topical corticosteroid use for radiographic procedures is permitted. Note: The use of physiologic corticosteroid replacement therapy may be approved after consultation with the sponsor.Xx_NEWLINE_xXReceiving immunosuppressive therapy including chronic steroids (except physiologic maintenance doses), methotrexate, or other known immunosuppressive agentsXx_NEWLINE_xXInhaled, intranasal, intraarticular, and topical steroids are permitted.Xx_NEWLINE_xXChronic administration (defined as daily or every other day for continuous use > 14 days) of systemic corticosteroids within 28 days of the first planned dose off PROSTVAC; use of inhaled steroids, nasal sprays, and topical creams for small body areas are allowedXx_NEWLINE_xXUse of prednisone or equivalent systemic corticosteroid within 2 weeks of treatment; use of inhaled, intranasal, intra-articular, and topical steroids is allowed; oral or IV steroids to prevent or treat IV contrast reactions are allowedXx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1, or anticipated requirement for systemic immunosuppressive medications during the trial\r\n* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the study chair\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone for adrenal insufficiency) is allowedXx_NEWLINE_xXSubjects, who have received previous systemic corticosteroids treatment or poorly absorbable corticosteroids for the treatment of aGVHD, for longer than 3 days (72 hours).Xx_NEWLINE_xXTreatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroids or steroids given for the purpose of adrenal replacement given at physiologic dosesXx_NEWLINE_xXPatients on immunosuppressive therapy including:\r\n* Systemic corticosteroid therapy for any reason; patients receiving inhaled or topical corticosteroids may participateXx_NEWLINE_xXSubject who used corticosteroids (excluding inhalers, eye-drops, and dermatologic corticosteroids) within 6 weeks prior to surgery;Xx_NEWLINE_xXPatients may not be on immunosuppressive therapy, including corticosteroids (with the exception of physiologic replacement, defined as 0.75 mg/m^2/day) at time of enrollment; however, patients who require intermittent use of bronchodilators or local steroid injections will not be excluded from the studyXx_NEWLINE_xXTreatment with systemic immunosuppressive medications including, but not limited to: prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Cycle 1, Day 1. Participants who have received acute and/or low-dose systemic immunosuppressant medications may be enrolled in the study after discussion with and approval by the Medical Monitor. The use of inhaled corticosteroids and mineralocorticoids for participants with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXConcomitant treatment with systemic corticosteroids greater than physiologic doses. Topical (other than at the proposed vaccination sites) or inhalational steroids are permittedXx_NEWLINE_xXReceiving systemic steroid therapy or any other form of systemic immunosuppressive therapy =< 7 days prior to registration; EXCEPTIONS:\r\n* Low doses of steroids (=< 20 mg of prednisone or equivalent dose of other steroid/day)\r\n* Previous use of corticosteroids is allowed\r\n* After initiation of MK-3475 therapy, steroid can be used for management of potential immune mediated adverse events (AE) for less than 8 weeks of therapy\r\n* Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) are permittedXx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial Cardiac Exclusion CriteriaXx_NEWLINE_xXPatients who are on chronic treatment with corticosteroids or other immunosuppressive agents (topical or inhaled corticosteroids are allowed)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab and tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, and topical steroids\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)Xx_NEWLINE_xXCorticosteroids: patients who are receiving dexamethasone or other corticosteroids must be on a stable or decreasing dose for at least 1 week prior to enrollment; it is recommended that patients be off all steroid therapy or receive the least dose that will control their neurologic symptomsXx_NEWLINE_xXInitiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers) within 1 week before administration of the first dose of study drug (patients already receiving erythropoietin on a chronic basis for >= 4 weeks are eligible)Xx_NEWLINE_xXPatients receiving systemic corticosteroids (patients off steroids for at least 48 hours are eligible)Xx_NEWLINE_xXConcomitant therapy with any of the following: interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroidsXx_NEWLINE_xXNo systemic corticosteroids (unless physiologic replacement dosing) within 7 days of enrollmentXx_NEWLINE_xXthe subject has been off systemic immunosuppressive medications (including but not limited to: cyclosporine, tacrolimus, mycophenolate mofetil, or corticosteroids) for at least 1 month prior to the first dose of GSK525762. Topical steroids are permittedXx_NEWLINE_xXAll cancer therapy, including radiation, topical steroid, and chemotherapy, must have been discontinued at least 1 week or 3 half-lives whichever is the longest prior to treatment in this study; the only exceptions are participants who are symptomatic from their skin lesions and have been on corticosteroids for prolonged periods of time (> 60 days) without change may continue use of either systemic steroid (equivalent to =< 10 mg per day of prednisone) or topical steroids are eligible for this study if the frequency and dosage steroids has not changed for 60 days prior to the study; these participants should continue on the same dose of systemic/topical steroid throughout the study period unless they achieve a complete response at which time steroids can be discontinued\r\n* Patients are allowed to continue any medications with known activity in T cell lymphomas at the pre-enrollment doses for conditions other than T cell lymphomas (i.e., steroids for sarcoidosis), as long as there is evidence of T cell lymphoma progression while patients were on these agentsXx_NEWLINE_xXCurrent treatment with systemic steroid therapy (inhaled/topical steroids are acceptable); systemic corticosteroids must be discontinued for at least 4 weeks prior to first treatment with ipilimumabXx_NEWLINE_xXUse of systemic corticosteroid therapy within 2 weeks of study enrollment, including patients receiving replacement corticosteroid therapy; note: only topical, inhaled and intranasal steroid therapy is permittedXx_NEWLINE_xXPatients who have received high doses of systemic corticosteroids for the treatment of their ATL within 4 weeks prior to the start of therapyXx_NEWLINE_xXUse of corticosteroids or other immunosuppression (if patient had been taking steroids, at least 2 weeks must have passed since the last dose)Xx_NEWLINE_xXConcurrent use of systemic steroids (within 10 days of enrollment) will be excluded, except for physiologic doses of systemic steroid replacement or local (topical, nasal, or inhaled) steroid use; limited doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease) must have completed at least 10 days prior to enrollment; steroid use to prevent intravenous (IV) contrast allergic reaction or anaphylaxis in patients who have known contrast allergies is allowed at any time prior to enrollmentXx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 1 week prior to cycle 1 day 1, or anticipated requirement for systemic immunosuppressive medications during the trial. Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone prior to the anthracycline-based chemotherapy for nausea) may be enrolled in the study. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed.Xx_NEWLINE_xXUse of corticosteroids or immunosuppressive medication is exclusionary, except the following in the absence of active autoimmune disease:\r\n* Subjects are permitted the use of corticosteroids with minimal systemic absorption (e.g. topical, ocular, intra articular, intranasal, and inhaled);\r\n* Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent are permitted;\r\n* Adrenal replacement steroid doses including doses > 10 mg daily prednisone are permitted;\r\n* A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g. CT scan premedication against contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by a contact allergen) is permitted.Xx_NEWLINE_xXActive autoimmune disease with reasonable possibility of clinically significant deterioration when receiving an immunostimulatory agent:\r\n* Subjects with type 1 diabetes mellitus, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.\r\n* Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg or 10 mg equivalent prednisone per day.\r\n* Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable.Xx_NEWLINE_xXPatients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent with the exceptions:\r\n* Diabetes type I, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible\r\n* Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg of prednisone or equivalent per day\r\n* Administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) is acceptableXx_NEWLINE_xXOngoing immunosuppressive treatment at the time of the start of voruciclib therapy, including systemic or enteric corticosteroids except as follows:Xx_NEWLINE_xXPrior to the start of voruciclib therapy, subjects may be using systemic corticosteroids (?20 mg/day of prednisone or equivalent), topical, or inhaled corticosteroidsXx_NEWLINE_xXDuring study therapy, subjects may use systemic, topical, or enteric corticosteroids, if neededXx_NEWLINE_xXEXCLUSION - DURVALUMAB DRUG-SPECIFIC: Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. The following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication).Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)Xx_NEWLINE_xXSubjects receiving systemic (oral or parenteral) corticosteroid therapy within 7 days of first dose of study drug or a requirement for chronic systemic immunosuppressive therapy for any reason. Topical or inhaled steroids are allowed.Xx_NEWLINE_xXPotential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 2 weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)Xx_NEWLINE_xXTreatment with systemic immunosuppressive medication;Xx_NEWLINE_xXPatients who are immunocompromised as follows: \r\n* Human immunodeficiency virus (HIV) positivity\r\n* Chronic administration (defined as daily or every other day for continued use > 14 days) of systemic corticosteroids or other immune suppressive drugs, within 28 days before treatment on study; nasal, or inhaled steroid, topical steroid creams and eye drops for small body areas are allowed\r\n* Patients who have undergone allogeneic peripheral stem cell transplantation, or solid organ transplantation requiring immuno-suppression\r\n** Active autoimmune disease, except patients with type 1 diabetes mellitus, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring current immuno-suppression, or with other endocrine disorders on replacement hormones or are not excluded if the condition is well controlledXx_NEWLINE_xXCurrent use of immunosuppressive medication, except for the following:\r\n* Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of treatment on this protocol, with the exceptions of:\r\n* Intranasal and inhaled corticosteroids\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent\r\n* Premedication for hypersensitivity reactions (e.g. to computed tomography [CT] contrast for scans).Xx_NEWLINE_xXSubjects on systemic intravenous or oral steroid therapy (or other immunosuppressive, such as azathioprine or cyclosporin A) are excluded; subjects must have had at least 6 weeks of discontinuation of any steroid therapy (except that used as premedication for chemotherapy or contrast-enhanced studies) prior to enrollment; physiologic (replacement) doses of steroids as well as nasal, topical or inhaled steroids are allowedXx_NEWLINE_xXAny systemic steroid therapy or other form of immunosuppressive therapy within 7 days of the first dose of the vaccine; a physiologic dose of systemic corticosteroids may be approved; inhaled or topical steroids, and adrenal replacement steroid doses =< 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent with the exceptions\r\n* Diabetes type I, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible\r\n* Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg of prednisone or equivalent per day\r\n* Administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) is acceptableXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXCurrent use of immunosuppressive medication, except for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)Xx_NEWLINE_xXRequirement for systemic corticosteroids unless used for adrenal replacement, acute therapy for asthma or bronchitis exacerbation (=< 2 weeks), or premedication for contrast allergy\r\n* Topical, intranasal, or inhaled steroids are not excludedXx_NEWLINE_xXPresence of immunosuppressive conditions, including administration of any medications or treatments that may adversely affect the immune system such as allergy injections, immune globulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids (oral or injectable) during 3 months prior to enrollment; inhaled and topical corticosteroids allowedXx_NEWLINE_xXActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent: a) Subjects with type I diabetes, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible; b) Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg of prednisone or equivalent per day; c) Administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) is acceptable.Xx_NEWLINE_xXPatients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drug.Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.Xx_NEWLINE_xXActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent with exception of:\r\n* Diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease or other mild autoimmune disorders not requiring immunosuppressive treatment\r\n* Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg of prednisone or equivalent per day\r\n* Administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) is acceptable\r\n* Subjects on systemic intravenous or oral corticosteroid therapy with the exception of physiologic doses of corticosteroids (=< the equivalent of prednisone 10 mg/day) or other immunosuppressives such as azathioprine or cyclosporin A are excluded on the basis of potential immune suppression; for these subjects these excluded treatments must be discontinued at least 1 weeks prior to enrollment for recent short course use (=< 14 days) or discontinued at least 4 weeks prior to enrollment for long term use (> 14 days); in addition, the use of corticosteroids as premedication for contrast-enhanced studies is allowed prior to enrollment and on studyXx_NEWLINE_xXOngoing immunosuppressive therapy other than corticosteroids.Xx_NEWLINE_xXOngoing immunosuppressive therapy, including systemic corticosteroids. Note: Subjects may be using topical or inhaled corticosteroids.Xx_NEWLINE_xXUse of intranasal and inhaled corticosteroids or systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent is permitted.Xx_NEWLINE_xXSystemic corticosteroids except as part of on label treatment prostate cancer regimens. Note: Topical applications (eg, rash), inhaled sprays (eg, obstructive airways diseases), eye drops or local injections (eg, intra-articular) are allowed.Xx_NEWLINE_xXTreatment with an immunosuppressive regimen of corticosteroids or other immunosuppressive medication (e.g., methotrexate, rapamycin) within 30 days of study treatment; Note: patients may take up to 5 mg of prednisone or equivalent daily; topical and inhaled corticosteroids in standard doses are allowedXx_NEWLINE_xXAll cancer therapy, including radiation, topical steroid, and chemotherapy must have been discontinued at least 1 week or 3 half-lives whichever is the longest prior to treatment in this study; the only exceptions are participants who are symptomatic from their skin lesions and have been on corticosteroids for prolonged periods of time (> 60 days) without change may continue use of either systemic steroids (equivalent to < 10 mg per day of prednisone) or topical steroids are eligible for this study if the frequency and dosage steroids has not changed for 60 days prior to the study; these participants should continue on the same dose of systemic/topical steroid throughout the study period unless they achieve a complete response at which time steroids can be discontinued; patients are allowed to continue any medications with known activity in T cell lymphomas at the pre-enrollment doses for conditions other than T cell lymphomas (ie, steroids for sarcoidosis), as long as there is evidence of T cell lymphoma progression while patients were on these agentsXx_NEWLINE_xXCurrent use of immunosuppressive medication, EXCEPT for the following:\r\n* Topical, ocular, intra-articular, intranasal, and inhaled corticosteroids.\r\n* Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone equivalent.\r\n* Steroids as premedication for hypersensitivity reactionsXx_NEWLINE_xXPatients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatmentXx_NEWLINE_xXParticipants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administrationXx_NEWLINE_xXMEDICATION-RELATED: Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.Xx_NEWLINE_xXSystemic corticosteroid therapy within 7 days before enrollment. Note: Topical and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowed. ? 5 mg/day of prednisone or equivalent doses of other corticosteroids are not allowed.Xx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration (i.e. disease-modifying antirheumatic drugs). Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Note that subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if >10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g. contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by contact allergen) is permitted.Xx_NEWLINE_xXActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent: * Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible \r\n* Current use of immunosuppressive medication, EXCEPT for the following: \r\n** Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); \r\n** Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent; \r\n** Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication).Xx_NEWLINE_xXCurrent use of immunosuppressive agents or systemic corticosteroids; topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption) are allowed; patients who have received systemic\r\ncorticosteroids =< 30 days prior to starting study drug will be excludedXx_NEWLINE_xXSubjects receiving topical steroids or other topical treatments for CTCL within 2 weeks.Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXNeed for systemic treatment with corticosteroids for cGVHDXx_NEWLINE_xXCorticosteroidsXx_NEWLINE_xXPatients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study entry are ineligibleXx_NEWLINE_xXConcurrent systemic corticosteroids, cytokines, and immunomodulatory therapy (e.g. interferons)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication 7 days before the first dose of nivolumab or ipilimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid; a brief course (=< 28 days) of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to randomisation, or anticipated requirement for systemic immunosuppressive medications during the trial Exclusion Criteria Related to Capecitabine:Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXSystemic treatment with either immunosuppressive doses of corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration\r\n* Subjects on a standard high-dose steroid taper after craniotomy or stereotactic biopsy may have received a higher dose of corticosteroids within 14 days of registration, however must be at a dose < 10 mg daily prednisone or bioequivalent per day within 5 days prior to initiation of study drug\r\n* Administration of steroids through a route known to result in a minimal systemic exposure (i.e., intranasal, intraocular, inhaled, topical, or local injection [e.g., intra-articular injection] corticosteroids [< 5% of body surface area]) are permitted in the absence of active autoimmune disease\r\n* Subjects requiring adrenal replacement with corticosteroids are eligible if the steroids are at doses =< 10 mg prednisone or bioequivalent per day in the absence of active autoimmune disease\r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication) are allowedXx_NEWLINE_xXHistory of venous thromboembolism within prior 6 months; chronic, systemic corticosteroid use for palliative or supportive purpose is not permitted; use of corticosteroids as symptomatic treatment may be allowed on individual basis and upon discussion with the sponsor; acute emergency administration, topical applications, inhaled sprays, eye drops or local injections of corticosteroids are allowedXx_NEWLINE_xXTreatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti?tumor necrosis factor alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the study, with the following exceptions:\r\n* Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study\r\n* Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study\r\n* Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)Xx_NEWLINE_xXCurrent use of medications specified by the protocol as prohibited for administration in combination with study drug; this includes patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to the start of study drug; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to start of study treatment.\r\n* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.Xx_NEWLINE_xXNo systemic corticosteroids (unless physiologic replacement dosing) within 7 days of enrollmentXx_NEWLINE_xXTreatment with any of the following medications or interventions within 28 days of registration:\r\n* Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable\r\n* Ketoconazole\r\n* High dose calcitriol [1,25(OH)2VitD] (i.e., > 7.0 ug/week)\r\n* Any other systemic therapy for prostate cancer (except for medical castration)Xx_NEWLINE_xXCorticosteroid use =< 14 days prior to registration; NOTE: Patients must be off systemic corticosteroids for at least 2 weeks prior to registration; this includes oral or IV route of administration; patients on chronic corticosteroids for adrenal insufficiency or other reasons may enroll if they receive less than 10 mg/day of prednisone (or equivalent); patients receiving inhaled or intranasal or intra-articular steroids are not excludedXx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications within past 4 weeks or 5 half-lives whichever is shorter. Use of inhaled or topical steroids or systemic corticosteroids < 10 mg/day of prednisone (or equivalent) is permittedXx_NEWLINE_xXChronic administration (defined as daily or every other day for continued use > 14 days) of systemic corticosteroids within 28 days before the first planned dose of investigational therapy; use of corticosteroids with minimal systemic absorption (e.g. inhaled steroids, nasal sprays, and topical agents) is allowedXx_NEWLINE_xXCurrent use of immunosuppressive medication, except for the following: \r\n* Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses ? 10 mg/day of prednisone or equivalent \r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Brief dosing for contrast allergy prophylaxis is allowed.Xx_NEWLINE_xXPatients receiving concomitant immunosuppressive agents or chronic corticosteroid use, except those on steroid to control brain metastases, those on topical or inhaled steroids, or steroids given via local injectionXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)Xx_NEWLINE_xXPatients who are on high dose steroid (e.g., > 10 mg prednisone daily or equivalent) or other more potent immune suppression medications (e.g., infliximab). Topical, inhaled, intraarticular, ocular, or intranasal corticosteroids (with minimal systemic absorption) are allowed. A brief course (< 48 hours) of systemic corticosteroids for prophylaxis (e.g., from contrast dye allergy) is permitted. Physiological corticosteroid replacement therapy for adrenal insufficiency is also permitted.Xx_NEWLINE_xXCurrent use of immunosuppressive medication, EXCEPT for the following:\r\n* Intranasal, inhaled, topical steroids, or local steroid injection (e.g. intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g. computed tomography [CT] scan premedication)Xx_NEWLINE_xXCondition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXSubjects with any condition or autoimmune disease that requires systemic corticosteroids (> 10 mg daily prednisone equivalents) or immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids are permittedXx_NEWLINE_xXConcurrent immunosuppressive therapy. A stable dose of prednisone <10 mg daily or inhaled corticosteroids are allowed.Xx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.Xx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra­-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXNo systemic corticosteroids (unless physiologic replacement dosing) within 7 days of enrollmentXx_NEWLINE_xXPotential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 2 weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication(s) within 14 days before study treatment is NOT permitted; the following are EXCEPTIONS to this criterion and are allowed\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)Xx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; systemic corticosteroids of less than 10 mg per day of prednisone (or equivalent) are allowed; topical corticosteroids are acceptable, including steroids with very low solubility administered nasally for local effects only (e.g. Nasonex)Xx_NEWLINE_xXNo immunosuppressive medications except non-systemic corticosteroidsXx_NEWLINE_xXPatients who are receiving systemic corticosteroidsXx_NEWLINE_xXCurrent use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication).Xx_NEWLINE_xXCurrent or prior use of any immunosuppressive medications, such as corticosteroids, within 14 days before enrollment\r\n* Oral hydrocortisone, only for the purposes of a documented and confirmed adrenal insufficiency diagnosis, is permitted if =< 25 mg daily total dose\r\n* Inhaled, intranasal, or topical corticosteroids are permittedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXHistory of severe asthma and currently on chronic systemic medications (mild asthma requiring inhaled steroids only is eligible)Xx_NEWLINE_xXNeed for systemic corticosteroids > 10 mg prednisone daily or equivalent alternative steroid (except physiologic dose for adrenal replacement therapy) or other immunosuppressive agents (such as cyclosporine or methotrexate); use of topical and inhaled corticosteroids is permittedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g. computed tomography [CT] scan premedication)\r\n* Receipt of live attenuated vaccine within 30 days prior to the first dose of IP; Note: patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IPXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of: intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid or steroids as pre-medication for hypersensitivity reactions (e.g. CT scan premedication).Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to study treatment; but: a. patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled; b. the use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXCurrent use of immunosuppressive medication, except for the following: \r\n* Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection) \r\n* Systemic corticosteroids at physiologic doses ? 10 mg/day of prednisone or equivalent \r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)Xx_NEWLINE_xXCurrent use or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal, inhaled, and intra-articular corticosteroids or systemic corticosteroids at physiological doses which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroidXx_NEWLINE_xXUse of systemic corticosteroidsXx_NEWLINE_xXCurrent usage of immunosuppressant medication except for a) intranasal, inhaled, and topical corticosteroids and b) systemic corticosteroids equivalent to =< 10 mg/day of prednisone, c) steroids as premedication for hypersensitivity reactions (e.g. computed tomography [CT] scan premedication)Xx_NEWLINE_xXConcurrent treatment with systemic corticosteroids (prednisone dose > 10 mg per day or equivalent) or other immunosuppressive drugs < 14 days prior to treatment initiation. Steroids that are topical, inhaled, nasal (spray), or ophthalmic solution are permitted.Xx_NEWLINE_xX(Atezolizumab-Related Exclusion) Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1 a) Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled. b) The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days prior to the first dose of durvalumab; the following are exceptions to this criterion: intranasal, inhaled, topical or local steroid injections (eg. intra-articular injection); steroids as premedication for hypersensitivity reactions; systemic corticosteroid at physiologic doses not to exceed 10mg/day of prednisone or equivalent; (NOTE: If systemic corticosteroids are part of the treatment regimen for the indication under study, the systemic corticosteroid is permitted)Xx_NEWLINE_xXPatients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 day of study drug administration; inhaled, ocular, intraarticular, intranasal, and topical steroids are permittedXx_NEWLINE_xXChronically treated with systemic doses of immunosuppressive drugs such as cyclosporin, ACTH, or corticosteroids.Xx_NEWLINE_xXAny condition that requires the use of corticosteroids outside of corticosteroids defined in the protocol after day 1 of therapyXx_NEWLINE_xXActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent:\r\n* Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible\r\n* Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg or 10 mg equivalent prednisone per day\r\n* Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptableXx_NEWLINE_xXCurrent use of immunosuppressive medication, EXCEPT for the following:\r\n* Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXPatients should not have any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug\r\n* NOTE: Inhaled or topical steroids and adrenal replacement steroids at any dose are permitted in the absence of active autoimmune disease; a brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permittedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti?tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1 day 1, or anticipated requirement for systemic immunosuppressive medications during the trial\r\n* Subjects who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids, physiologic replacement doses of glucocorticoids (i.e., for adrenal insufficiency), and mineralocorticoids (e.g., fludrocortisone for adrenal insufficiency) is allowedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXThe following treatments must be discontinued:\r\n* Herbal medications\r\n* Immunomodulatory agents, including but not limited to interferons or IL-2\r\n* Immunosuppressive medications, including but not limited to cyclophosphamide, azathioprine, methotrexate, and thalidomide\r\n* Systemic corticosteroids\r\n* Anti?TNF-alpha agentsXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab with the exceptions of premedication and intranasal, topical and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXPrior or currently active autoimmune disease requiring management with immunosuppression; this includes inflammatory bowel disease, ulcerative colitis, Crohn’s disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication (e.g., corticosteroids) which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines; in the case of asthma or chronic obstructive pulmonary disease taking inhaled corticosteroids that does not require daily systemic corticosteroids is acceptable; additionally, local acting steroids (topical, inhaled, or intraarticular) will be allowed; patients on intermittent or short course steroids will be allow if the dose does not exceed 4 mg of dexamethasone (or equivalent) per day for > 7 consecutive days; any patients receiving steroids should be discussed with the principal investigator (PI) to determine if eligibleXx_NEWLINE_xXTreatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroidsXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXCurrent use of corticosteroid therapy > 5 mg/day of prednisone or equivalent doses of other corticosteroids (topical, intranasal, and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowed)Xx_NEWLINE_xXUse of systemic chronic steroid therapy (?10mg /day of prednisone or equivalent), or any immunosuppressive therapy within 7 days of first dose of study treatment. Topical, inhaled, nasal, or ophthalmic steroids are allowed.Xx_NEWLINE_xXCurrently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)Xx_NEWLINE_xXPatients who have a condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration are not eligible. However, inhaled or topical steroids, adrenal replacement doses, and > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients are excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; subjects are permitted to use topical, ocular, intraarticular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXSubject is currently receiving or has received systemic corticosteroids <14 days prior to starting study drugs. The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular).Xx_NEWLINE_xXOngoing requirement for an immunosuppressive treatment, including the use of glucocorticoids or cyclosporine, or with a history of chronic use of any such medication within the last 4 weeks before enrollment; patients are excluded if they have any concurrent medical condition that requires the use of systemic steroids (the use of inhaled or topical steroids is permitted)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy (excludes inhaled corticosteroids) within 7 days of study registrationXx_NEWLINE_xXHistory of severe asthma and currently on chronic systemic medications (mild asthma requiring inhaled steroids only is eligible)Xx_NEWLINE_xXUse of systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications < 14 days of registration\r\n* Note: inhaled or topical steroids are permitted; > 10 mg daily prednisone equivalents are permitted only in adrenal insufficiency in the absence of active autoimmune diseaseXx_NEWLINE_xXActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent:\r\n* Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible\r\n* Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg or 10 mg equivalent prednisone per day \r\n* Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptableXx_NEWLINE_xXConcurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical, nasal, eye drops or inhaled) steroid use; limited doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent IV contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowedXx_NEWLINE_xXCurrently taking immunosuppressive drugs within 28 days of study product injection (with exception of corticosteroids for tumor treatment)Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization; inhaled or topical steroids are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment\r\n* The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXCurrent use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)Xx_NEWLINE_xXActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent:\r\n* Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible\r\n* Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg or 10 mg equivalent prednisone per day\r\n* Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptableXx_NEWLINE_xXCurrent use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (eg, intra-articular injection); b. systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)Xx_NEWLINE_xXAble to be off prednisone or other systemic immunosuppressive medications for at least 3 days prior to NK cell infusion (excluding preparative regimen pre-medications)Xx_NEWLINE_xXHistory of severe asthma and currently on systemic chronic medications (mild asthma requiring inhaled steroids only is eligible)Xx_NEWLINE_xXPatients requiring steroids or other immunosuppressive therapy; low-dose or topical steroids are allowable if being used as replacement therapyXx_NEWLINE_xXPatients must be off all systemic immunosuppressive drugs including corticosteroids at any dose for at least 28 days prior to protocol enrollment and must remain off immunosuppressive drugs while enrolled on the protocol; patients must not be taking any systemic steroids at all for 14 days prior to apheresis and initiation of chemotherapy; topical corticosteroid preparations applied to the skin such as solutions, creams, and ointments are allowed; inhaled corticosteroids are allowed, and corticosteroid eye drops are allowedXx_NEWLINE_xXPatients are ineligible who have any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications =< 14 days prior to registration\r\n* NOTE: inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; a brief (less than 3 weeks) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by a contact allergen) is permittedXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXPatients receiving chronic, high dose systemic treatment with corticosteroids defined as: chronic use of cortisone > 50mg; hydrocortisone > 40mg, prednisone > 10mg, methylprednisone > 8mg or dexamethasone > 1.5mg; or another immunosuppressive agent; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab OR tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Steroid premedication for the prevention of radiologic contrast hypersensitivity is allowed.Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 4 mg daily dexamethasone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXPresence of condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXSubjects with diagnosis of immunodeficiency or who are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; the following are exceptions to this exclusion criteria: intranasal, inhaled, topical steroids, or local steroids injections (e.g. intra-articular injection); systemic corticosteroids at physiologic dose not to exceed 10 mg/day of prednisone or equivalent; steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)Xx_NEWLINE_xXPatients with conditions requiring high doses of steroids or other immunosuppressive medications are excluded.Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications including but not limited to: prednisone, dexamethasone, cyclosporin, azathioprine, methotrexate, thalidomide, anti-tumor necrosis factor (TNF) agents within 2 weeks of first study dose\r\n* Subjects who have received acute, low-dose systemic immunosuppressant medications may be enrolled (such as steroids for acute nausea or cancer-related pain =< 10 mg prednisone) may be enrolled sooner than 2 weeks of first study dose\r\n* Subjects with adrenal insufficiency on physiologic replacement doses of steroids may be enrolled (=< 10 mg prednisone)\r\n* The use of inhaled, topical, ocular or intra-articular corticosteroids and mineralocorticoids are allowedXx_NEWLINE_xXHas received systemic immunosuppressive treatments, aside from systemic corticosteroids (such as methotrexate, chloroquine, azathioprine, etc) within six months of registrationXx_NEWLINE_xXInitiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers) within 1 week before administration of the first dose of study drug (participants already receiving erythropoietin on a chronic basis for >=4 weeks are eligible).Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab (MEDI4736) or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXPatients receiving corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drugXx_NEWLINE_xXUse of chronic corticosteroids, hydroxyurea, or immunomodulating agents (e.g., interleukin 2, interferon alpha or gamma, granulocyte colony stimulating factors, etc.) within 30 days prior to study entry\r\n* NOTE: recent or current use of inhaled steroids is not exclusionary; if subjects are prescribed a brief course of oral corticosteroids, the use should be limited to less than 7 days; isolated use of steroids as premedication for medical procedures to minimize allergic reaction e.g. CT scan dye are allowedXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; subjects may use topical or inhaled corticosteroids or low-dose steroids (=< 10 mg of prednisone or equivalent per day) as therapy for comorbid conditions; during study participation, subjects may receive systemic or enteric corticosteroids as needed for treatment-emergent comorbid conditionsXx_NEWLINE_xXPatients who are on high dose steroid (e.g., > 10 mg prednisone daily or equivalent) or other more potent immune suppression medications (e.g., infliximab); topical, inhaled, intra-articular, ocular, or intranasal corticosteroids (with minimal systemic absorption) are allowed; a brief course (=< 48 hours) of systemic corticosteroids for prophylaxis (e.g., from contrast dye allergy) is permittedXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXImmunosuppressive medication within 14 days prior to the first dose of study treatment; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days\r\n* Systemic corticosteroids at physiologic doses of < 10 mg/day of prednisone or equivalentXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal, topical, and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXCurrent use of immunosuppressive medication, except the following:\r\n* Subjects are permitted the use of corticosteroids with minimal systemic absorption (e.g. topical, intra-articular, intranasal, and inhaled);\r\n* Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent are permitted;\r\n* A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g. CT scan premedication against contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by a contact allergen) is permittedXx_NEWLINE_xXMedical need for systemic corticosteroids > 10 mg prednisone daily or equivalent alternative steroid (except physiologic dose for adrenal replacement therapy) or other immunosuppressive agents (such as cyclosporine or methotrexate); topical and inhaled corticosteroids are allowed if medically neededXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients receiving systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drugXx_NEWLINE_xXHas received the following within 7 days prior to study day 1:\r\n* Allergy desensitization injections\r\n* Systemic corticosteroids of more than 10 mg per day of prednisone (or equivalent), and administered parenterally or orally, except for physiologic replacement; inhaled steroids (e.g. Advair, Flovent, Azmacort) are not permitted; topical corticosteroids are acceptable, including steroids with very low solubility administered nasally for local effects only (e.g. Nasonex)Xx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXSubjects must be off of all immunosuppressive medications for a minimum of 2 weeks with the exception of physiologic doses of corticosteroidsXx_NEWLINE_xXCurrently receiving or has received systemic corticosteroids within 4 weeks prior to starting study drug for management of brain metastases, or who have not fully recovered from side effects of such treatment; steroids for endocrine replacement or receipt of short-course of steroids during the preceding 4 week period as supportive medication such as for drug allergy, anti-emetic, etc. is allowed)Xx_NEWLINE_xXActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent: a) subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible; b) subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg or 10 mg equivalent prednisone per day; c) administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptableXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; subjects may use topical or inhaled corticosteroids or low-dose steroids (=< 10 mg of prednisone or equivalent per day) as therapy for comorbid conditions; during study participation, subjects may receive systemic or enteric corticosteroids as needed for treatment-emergent comorbid conditionsXx_NEWLINE_xXHas a diagnosis of immunosuppression or is receiving ongoing immunosuppressive therapy, including systemic or enteric corticosteroids for treatment of lymphoid cancer or other conditions\r\n* Note: subjects may use topical or inhaled corticosteroids or low-dose steroids (=< 20 mg of prednisone or equivalent per day) as therapy for comorbid conditions; during study participation, subjects may also receive systemic or enteric corticosteroids as needed for treatment-related toxicitiesXx_NEWLINE_xXConcurrent use of systemic steroids or steroid eye drops; this is to avoid immunosuppression which may lead to potential complications with vaccinia (priming vaccination); nasal, topical or inhaled steroid use is permittedXx_NEWLINE_xXTreatment with an immunosuppressive regimen of corticosteroids or other immunosuppressive medication (e.g., methotrexate, rapamycin) within 30 days of study treatment; Note: subjects may take up to 5 mg of prednisone or equivalent daily; topical and inhaled corticosteroids in standard doses are allowedXx_NEWLINE_xXCurrent use of systemic corticosteroids or use of systemic corticosteroids within 4 weeks of enrollment (inhaled corticosteroids for asthma or chronic obstructive pulmonary disease [COPD] are permitted as are other non-systemic steroids such as topical corticosteroids)Xx_NEWLINE_xXNo concomitant therapy with any of the following: IL-2, interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids.Xx_NEWLINE_xXPatients are excluded if they have any concurrent medical condition requiring the use of systemic steroids (the use of inhaled or topical steroids is permitted).Xx_NEWLINE_xXRequire systemic treatment with either corticosteroids (> 8 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXPatients should not have any condition requiring systemic treatment with corticosteroids (< 10 mg daily prednisone equivalents) or other immunosuppressive medications =< 14 days prior to registration\r\n* NOTE: Inhaled or topical steroids and adrenal replacement steroid doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; a brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permittedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of nivolumab, with the exceptions of intranasal, topical, and inhaled corticosteroids or systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent (use for brain metastases is not permitted 28 days prior to start of therapy)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXNo systemic glucocorticoids will be permitted within 48 hours prior to study registration\r\n* Note: Topical steroids, bronchodilators and local steroid injections are permitted if clinically requiredXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXAnticancer topical therapy, including therapeutic doses of steroids, within 2 weeks prior to initiating study treatment; Note: Topical steroids at doses intended for symptom management are permitted prior to study enrollment and may continue during study treatmentXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days prior to the first dose of MEDI4736 or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)Xx_NEWLINE_xXConcurrent medical condition requiring the use of immunosuppressive medications, or systemic steroids; topical corticosteroids are allowedXx_NEWLINE_xXPatients who have a diagnosis of immunodeficiency (per PI discretion) or who have received treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents =< 14 days prior to study registration are not eligible\r\n* NOTE: patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., one-time dose of dexamethasone for nausea) may be enrolled in the study; the use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowedXx_NEWLINE_xXPatient has history of primary immunodeficiency OR has received any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, excluding intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses; attempts should be made to have patient on lowest possible dose of steroids (acceptable range 4-10 mg, please contact PI if dose is > 4 mg) and weaned to off as is feasibleXx_NEWLINE_xXPotential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 2 weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)Xx_NEWLINE_xXSystemic steroids should be stopped 2 weeks before the start of treatment; topical and inhaled steroids are allowedXx_NEWLINE_xXCurrent systemic steroid therapy (inhaled or topical steroids are also not allowed)Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXPatients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drugXx_NEWLINE_xXIf receiving corticosteroids, patients must be on a stable or decreasing dose of corticosteroids for ? 5 days prior to baseline MRI.Xx_NEWLINE_xXPatients must have discontinued systemic antineoplastic therapy (including systemic corticosteroids and excluding tyrosine kinase inhibitors for CML) at least four (4) weeks prior to enrollment.Xx_NEWLINE_xXActive immunosuppressive or cytotoxic therapy (excluding topical steroids) for any other condition.Xx_NEWLINE_xXAny chronic medical condition requiring a higher dose of corticosteroid than 10mg prednisone/prednisolone daily; use of inhaled, intranasal, intra-articular and topical steroids is acceptable, as is a short course (i.e. =< 1 day) of corticosteroids to prevent a reaction to the IV contrast used for CT scansXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXTreatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroidsXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agentsXx_NEWLINE_xXPatients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications.Xx_NEWLINE_xXTreatment with corticosteroids in the last 3-week period before inclusion, except for topical, ocular, intra-articular, intranasal, and inhaled corticosteroids with minimal systemic absorption (e.g. with a dose ? 500 microgram beclomethasone equivalent for inhaled steroids), or adrenal replacement steroid doses ? 10 mg daily prednisone equivalent which are permitted.Xx_NEWLINE_xXPotential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 4 weeks prior to enrollment (inhaled or topical steroids at standard doses or isolated use of steroids as premedication for medical procedures to minimize allergic reaction [e.g. computed tomography (CT) scan dye] are allowed)Xx_NEWLINE_xXChronic administration (defined as daily or every other day for continued use > 14 days) of corticosteroids deemed systemic by investigator within 28 days before the first planned dose of PROSTVAC; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowedXx_NEWLINE_xXConcurrent use of systemic steroids or chronic use of immunosuppressant medications; recent or current use of inhaled steroids is not exclusionaryXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of MEDI4736 and tremelimumab with the exceptions of intranasal and inhaled corticosteroids, systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent, or steroids used transiently to control contrast agent allergies for radiographic studiesXx_NEWLINE_xXHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy at doses >= 10 mg prednisone or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of trial treatment; subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents; a brief course (=< 28 days) of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXConcurrent use of systemic steroids or immunosuppressant medications; recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionaryXx_NEWLINE_xXInitiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers) within 1 week before administration of the first dose of study drug (patients already receiving erythropoietin on a chronic basis for >= 4 weeks are eligible)Xx_NEWLINE_xXPatients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drugXx_NEWLINE_xXPatients must not receive concurrent systemic or topical steroids or other skin directed therapy while on studyXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPermitted therapies include topical, ocular, intra?articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of nonautoimmune conditions (e.g. delayed?type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug, or has not fully recovered from side effects of such treatment; the following uses of corticosteroids are permitted: single doses, topical application (e.g., for rash), inhaled sprays (e.g., for obstructive airway diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXImmunosuppressive therapy including systemic corticosteroids except for maintenance dosing for adrenal insufficiencyXx_NEWLINE_xXConcurrent use of systemic steroids or immunosuppressant medications; recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionaryXx_NEWLINE_xXHave a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients on immunosuppressive agentsXx_NEWLINE_xXSubjects requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days prior to the first treatment.Xx_NEWLINE_xXCurrent or prior use of immunosuppressive therapy within 14 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXPatients receiving systemic steroid therapy for a chronic inflammatory condition (e.g., rheumatoid arthritis, Crohn's Disease, etc.). Topical steroids are also excluded. Nasal and inhaled steroids are permitted.Xx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents), or anticipated requirement for systemic immunosuppressive medications during the trial; patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone prior to the anthracycline-based chemotherapy for nausea) may be enrolled in the study; the use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowedXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of investigational product (IP). The following are exceptions to this criterion: • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection) • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).Xx_NEWLINE_xXPatients requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalents) or immunosuppressive medications within 14 days of enrollmentXx_NEWLINE_xXHave a diagnosis of immunodeficiency, either primary or acquired, or treatment with systemic steroids or any other form of immunosuppressive therapy within 7 days prior to C1D1. Exception: inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease as well as a one-time dose of immunosuppressive agents used prophylactically for contrast allergiesXx_NEWLINE_xXReceiving immunosuppressive therapy including chronic steroids, methotrexate, or other known immunosuppressive agentsXx_NEWLINE_xXParticipants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administrationXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXTreatment with any of the following medications within 28 days of registration, or while on study, is prohibited:\r\n* Systemic corticosteroids (at doses over the equivalent of 5 mg prednisone daily) - not permitted within 1 month of registration; inhaled, intranasal or topical corticosteroids are acceptable\r\n* Prostate cancer (PC)-SPES\r\n* Saw palmetto\r\n* Megestrol\r\n* Ketoconazole\r\n* 5-alpha-reductase inhibitors - patients already taking 5-alpha-reductase inhibitors prior to 28 days prior to registration may stay on these agents throughout the course of therapy, but these should not be started while patients are on study\r\n* Diethylstilbestrol\r\n* Abiraterone\r\n* Enzalutamide\r\n* Radium 223 (Xofigo)\r\n* Any other hormonal agent or supplement being used with the intent of cancer treatmentXx_NEWLINE_xXNo systemic oral steroids administered within 28 days prior to initiating treatment on protocol; topical, ocular, and nasal steroids are allowed, as are those applied to mucus membranesXx_NEWLINE_xXNot currently receiving immunosuppressive drugs such as corticosteroids (excluding topical treatment), tacrolimus or cyclosporineXx_NEWLINE_xXCurrent use of immunosuppressive drugs or use of corticosteroids, except for inhaler, topical corticosteroids, or dexamethasone in the premedication for docetaxel.Xx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXPatients being chronically treated with immunosuppressive drugs such as cyclosporin, adrenocorticotropic hormone (ACTH), or systemic corticosteroidsXx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, anti-tumor necrosis factor agents) within 2 weeks prior to enrollment or anticipated requirement for systemic immunosuppressive medications during the trial\r\n* Patients who have received acute, low dose, systemic immunosuppressant medication (e.g., a one-time dose of dexamethasone for nausea) may be enrolled after a discussion and approval by the principal investigator\r\n* The use of inhaled corticosteroids and mineralocorticoids (eg, fludrocortisone) is allowedXx_NEWLINE_xXPatients with graft versus host disease (GVHD) active < grade 2 who are on a stable dose of immunosuppressive therapy (tacrolimus, cyclosporine, or other) for > 2 weeks will be included; Note: subjects may be using systemic corticosteroids or topical or inhaled corticosteroidsXx_NEWLINE_xXPrior or current systemic immunosuppressive therapy (> 10 mg/day prednisone equivalents) within 1 week prior to C1D1 of study therapy; inhaled, ocular, intra-articular, intranasal, and topical corticosteroids are permitted in absence of active autoimmune disease\r\n* Adrenal replacement doses are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXChronic treatment with high dose corticosteroids or other immunosuppressive agents; topical, inhaled, and low dose oral corticosteroids are allowed provided stable dosing for at least 2 weeksXx_NEWLINE_xXHas received Hematopoietic Stem Cell Transplantation (HSCT) within 60 days of the first dose of DS-3032b, is on immunosuppressive therapy post-HSCT at the time of screening, or has clinically significant GVHD (use of topical steroids for ongoing skin GVHD will be permitted). Subjects must have a washout period of >=2 weeks or at least 4 half-lives from their last systemic immunosuppressive treatment for GVHD.Xx_NEWLINE_xXConditions that would prohibit administration of corticosteroidsXx_NEWLINE_xXNo systemic corticosteroids (unless physiologic replacement dosing) within 7 days of enrollmentXx_NEWLINE_xXSubjects who require or are likely to require more than a two-week course of corticosteroids for intercurrent illness; subjects must complete therapy prior to enrollment; topical corticosteroids should be stopped at least 2 weeks prior to enrollment and systemic corticosteroids should be stopped at least 4 weeks prior to enrollmentXx_NEWLINE_xXSubjects are excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement steroid doses are permitted in the absence of active autoimmune disease; drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab?containing regimenXx_NEWLINE_xXConcomitant therapy with any of the following: interleukin (IL)-2, interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids while receiving ipilimumab (as long as steroid replacement is significantly greater than what is required for physiologic replacement, i.e. in hypothyroidism)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXDependence on corticosteroids\r\n* Steroid dependence can be defined as a medical need to be greater than 5 mg of prednisone (or equivalent doses of other systemic steroids) a day, chronically; higher doses need to be avoided for at least 3 days prior to leukapheresis and, again, for at least 3 days prior to T cell infusion and up to at least 3 months after T cell infusion unless medically indicated to treat a new toxicity\r\n* Note: topical and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowedXx_NEWLINE_xXPatients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatmentXx_NEWLINE_xXDependence on corticosteroids\r\n* Defined as doses of corticosteroids of greater than 5 mg/day of prednisone or equivalent doses of other corticosteroids\r\n* Note: topical and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowed\r\n* Please note that this criterion is not applicable if the research participant's donor is undergoing leukapheresisXx_NEWLINE_xXOngoing use of other immunosuppressive medications, including oral steroids and excluding topical steroidsXx_NEWLINE_xXPatients receiving chronic treatment with steroids or another immunosuppressive agent\r\n* Note: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are allowed; patients with previously treated brain metastases, who are on stable low dose corticosteroids treatment (e.g. dexamethasone 2 mg/day, prednisolone 10 mg/day) for at least 14 days before start of study treatment are eligibleXx_NEWLINE_xXTreatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroidsXx_NEWLINE_xXSubjects taking systemic (parentally or orally) corticosteroid therapy for any reason, including replacement therapy for hypoadrenalism, are not eligible. Topical steroids are acceptable as are intranasal steroids.Xx_NEWLINE_xXPatients who require pharmacologic doses of corticosteroids; replacement, topical, ophthalmologic and inhalational steroids are permitted.Xx_NEWLINE_xXConcurrent use of systemic steroids or immunosuppressant medicationsXx_NEWLINE_xXConcurrent use of systemic steroids; recent or current use of inhaled steroids is not exclusionaryXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed, and treatment with low dose Decadron (=< 3mg daily) is allowedXx_NEWLINE_xXConcomitant therapy with any of the following: interleukin (IL)-2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids in the previous 4 weeksXx_NEWLINE_xXPatients who have received any of the following concomitant therapy: interleukin (IL)-2, interferon or other non-study immunotherapy regimens; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses) within 28 days prior to first doseXx_NEWLINE_xXSubjects required to take corticosteroids or other immunosuppressive therapy such as those with organ allograftXx_NEWLINE_xXEvidence of immune dysfunction as listed below:\r\n* Human immunodeficiency virus (HIV) positivity\r\n* Active autoimmune diseases requiring treatment or a history of autoimmune disease that might be stimulated by vaccine treatment; however, patients with vitiligo may be enrolled\r\n* Concurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical, nasal, or inhaled) steroid use; limited doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent intravenous [IV] contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowedXx_NEWLINE_xXPatients using immunosuppressive medications or other medications that may increase radiation toxicity such as methotrexate, sirolimus, tacrolimus, or colchicine that are unable to discontinue these medications during SBRT course; use of corticosteroids are not considered an exclusion criteriaXx_NEWLINE_xXPatients taking systemic corticosteroidsXx_NEWLINE_xXSystemic corticosteroid use within past 14 days; use of inhaled, intranasal, and topical steroids is acceptableXx_NEWLINE_xXPotential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 4 weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)Xx_NEWLINE_xXIncreasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agentXx_NEWLINE_xXConcomitant therapy with any of the following: tamoxifen, toremifene, IL2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids greater than physiologic replacement doses; ocular steroid use is acceptableXx_NEWLINE_xXUse of systemic immunosuppressive medications, including corticosteroids, tacrolimus, mycophenolate mofetil, sirolimus or cyclosporine AXx_NEWLINE_xXThe use of corticosteroids to control cerebral edema or treat neurologic symptoms will not be allowed, and patients who previously required corticosteroids for symptom control must be off steroids for at least 3 days without recurrence of symptoms prior to starting trial therapy; corticosteroids for other indications is allowedXx_NEWLINE_xXPatients must be off systemic immunosuppressive medications > 2 weeks prior to treatment start; if patients are in systemic corticosteroids and must be on a dose of prednisone 5 mg/day or less (or equivalent), then patients must be on this reduced dose for > 1 week prior to treatment start; topical steroids are allowedXx_NEWLINE_xXShort course systemic corticosteroids for disease control, improvement of performance status or non-cancer indication (=< 7 days) must have been discontinued at least 6 days prior to study treatment; stable ongoing corticosteroid use (>= 30 days) up to an equivalent dose of 20 mg of prednisone is permissible\r\n* CTCL: Topical steroids that have been used for > 3 weeks may be continued\r\n* All other histologies (not CTCL): Topical steroids use is permissible without restrictionXx_NEWLINE_xXHave brain metastases that are neurologically unstable or require an increasing dose of corticosteroids. Patients must be on a stable or decreasing dose of corticosteroids for 7 days prior to first dose of AP32788.Xx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXChronic treatment with systemic steroids or other immunosuppressive agents; Note: topical or inhaled steroids are allowedXx_NEWLINE_xXCurrent use of systemic corticosteroidsXx_NEWLINE_xXUnder active treatment with immunosuppressive agents such as systemic corticosteroids or cyclosporine that cannot be discontinued before starting rRp450 infusionsXx_NEWLINE_xXChronic treatment with systemic steroids or another immunosuppressive agent with the following exceptions:\r\n* Intermittent steroids may be used on an as-needed basis (e.g. treatment for chemotherapy-related nausea)\r\n* Patients on physiologic replacement doses of steroids due to adrenal insufficiency for any reason may remain on these medicationsXx_NEWLINE_xXNo systemic oral steroids administered within 28 days prior to initiating treatment on protocol; topical, ocular, and nasal steroids are allowed, as are those applied to mucus membranesXx_NEWLINE_xXMore than 4 weeks since prior systemic corticosteroidsXx_NEWLINE_xXCorticosteroids by aerosol are allowedXx_NEWLINE_xXHistory of organ transplant requiring immunosuppression; or history of pneumonitis or interstitial lung disease requiring treatment with systemic steroids; or a history of receiving systemic steroid therapy or any other immunosuppressive medication ? 3 days prior to study initiation. Daily steroid replacement therapy (eg, prednisone or hydrocortisone) and corticosteroid use to manage AEs are permitted.Xx_NEWLINE_xXCorticosteroids: Participants receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to study drug administration (except when indicated for Central Nervous System [CNS] metastases, then participants must not have received corticosteroids for at least 28 days)Xx_NEWLINE_xXUse of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to study treatment.Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab and tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent\r\n* Steroids as pre-medication for hypersensitivity reactions (e.g., CT scan pre-medication)Xx_NEWLINE_xXSubject is receiving concomitant immunosuppressive therapy, defined as:\r\n* Immunosuppressants, including: tacrolimus, sirolimus, everolimus, cyclosporine, azathioprine, mycophenolate mofetil, antithymocyte globulin, basiliximab, belatacept\r\n* Systemic corticosteroids (except for short team treatment of allergic reactions or for treatment of immune related adverse events [irAE]); steroids with no or minimal systemic effect (topical, inhalation) are allowed\r\n* Chemotherapy\r\n* Immunotherapy\r\n* Monoclonal antibodiesXx_NEWLINE_xXSystemic immunosuppressive medications such as steroids; the following steroid formulations are permitted: intranasal, intra-articular, and inhaled steroidsXx_NEWLINE_xXAny condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption)' physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXActive or prior history of autoimmune or inflammatory condition requiring ongoing immunosuppressive medications. This specifically includes use of immunosuppressive medication within 28 days before the first dose of durvalumab with the exceptions of intranasal corticosteroids or systemic corticosteroids at physiological doses, which do not exceed 10mg/day of prednisone or an equivalent corticosteroid.Xx_NEWLINE_xXHistory of severe asthma and currently on chronic systemic medications (mild asthma requiring inhaled steroids only is eligible)Xx_NEWLINE_xXSystemic chronic steroid therapy (? 10mg/day prednisone or equivalent) or any immunosuppressive therapy 7 days prior to planned date for first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids are allowed.Xx_NEWLINE_xXSubjects on chronic steroid therapy > 5 mg/day within 2 weeks of screening except for inhaled, nasal, or topical steroidsXx_NEWLINE_xXActive autoimmune disease or any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.Xx_NEWLINE_xXOngoing immunosuppressive therapy, including systemic corticosteroids (> 10 mg prednisone or equivalent/day) with the exception of the use of topical, enteric, or inhaled corticosteroids as therapy for comorbid conditions and systemic steroids for autoimmune anemia and/or thrombocytopeniaXx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to Day 1 of Cycle 1, or anticipated requirement for systemic immunosuppressive medications during the trialXx_NEWLINE_xXActive immunosuppressive therapy (excluding topical steroids) for any other condition.Xx_NEWLINE_xXAt least 2 weeks beyond corticosteroids.Xx_NEWLINE_xXPatients who have received corticosteroids =< 2 weeks prior to starting study drug; the exception is patients receiving low dose steroids for CNS disease; otherwise, systemic corticosteroids should not be administered with BKM120Xx_NEWLINE_xXGvHD requiring systemic immunosuppressive therapyXx_NEWLINE_xXPatients on immunosuppressive therapy including:\r\n* Systemic corticosteroid therapy for any reason; patients receiving inhaled, intranasal or topical corticosteroids may participateXx_NEWLINE_xXNote: Current or recent use of intra-articular, topical or inhaled glucocorticoid therapy is acceptable;Xx_NEWLINE_xXIntranasal, inhaled, or topical steroids or local steroid injections (eg, intra-articular injection) are permitted;Xx_NEWLINE_xXSubjects who require immunosuppressive medications such as methotrexate, tumor necrosis factor inhibitors, or systemic corticosteroids (>10 mg/day prednisone equivalents) within 2 weeks prior to study drug administration. Inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.Xx_NEWLINE_xXPatients who have received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti TNF] agents) within 2 weeks before initiation of study treatment\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids, and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti?tumor necrosis [anti-TNF] factor agents) within 14 days prior to randomization or anticipation of need for systemic immunosuppressive medications during the study; Note: Intranasal and inhaled corticosteroids or systemic corticosteroids at doses that do not exceed 10 mg/day of prednisone or an equivalent corticosteroid are allowedXx_NEWLINE_xXORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Daily administration of systemic immunosuppressive therapy or corticosteroids (except in physiological doses for hormone deficiency) during the previous 30 daysXx_NEWLINE_xXHPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Daily administration of systemic immunosuppressive therapy or corticosteroids (except in physiological doses for hormone deficiency) during the previous 30 daysXx_NEWLINE_xXAny use of systemic corticosteroids within 10 days of treatment initiation.Xx_NEWLINE_xXHave significant immunosuppression from concurrent, recent, or anticipated need for chronic treatment with systemic immunosuppressive dose of corticosteroids or immunosuppressive medications.Xx_NEWLINE_xXHas a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). A brief course of corticosteroids for prophylaxis (e.g. contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by contact allergens) is permittedXx_NEWLINE_xXConcomitant therapy indicated with any of the following: interferons or other non-study immunotherapy regimens; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroidsXx_NEWLINE_xXSubject is currently using or has used immunosuppressive medication within 14 days prior to the first dose of study treatment; the following are exceptions:\r\n* Intranasal, topical, inhaled, or local steroid injections (e.g., intra-articular injection)\r\n* Chronic systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reaction (e.g., infusion-related reactions, computed tomography [CT] scan premedication)Xx_NEWLINE_xXPatients must not be receiving chronic systemic corticosteroids at doses greater than physiologic dosing (inhaled corticosteroids acceptable).Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1. (Patients who have received acute, low dose, systemic immunosuppressant medications [e.g., a one-time dose of dexamethasone for nausea] may be enrolled. The use of inhaled corticosteroids and mineralocorticoids [e.g., fludrocortisone] for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.)Xx_NEWLINE_xXCurrent or prior use of systemic immunosuppressive medication within 28 days before the first dose of durvalumab + trabectedin, with the exception of systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid; the following are exceptions to this criterion:\r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) =< 2 weeks prior to registration\r\n* Note:\r\n** Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n** The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab and tremelimumab with the exceptions of intranasal and inhaled corticosteroids, systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent, or steroids used transiently to control contrast agent allergies for radiographic studiesXx_NEWLINE_xXSignificant immunosuppression from concurrent, recent (=< 4 weeks ago) or anticipated treatment with systemic corticosteroids at any dose, or other immunosuppressive medications such as methotrexate, cyclosporine, azathioprine (antihistamines, non-steroidal anti-inflammatory drugs and aspirin permitted) or conditions such as common variable hypogammaglobulinemia or exposures such as large field radiotherapy.Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days prior to first study dose, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent. Steroids as premedication for hypersensitivity reactions due to radiographic contrast agents are allowed.Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and TNFalpha antagonists) within 28 days prior to week 1, day 1\r\n* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the study co-chairs.\r\n* The use of inhaled, intranasal, ophthalmic or topical corticosteroids is allowed\r\n* The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension is allowed.\r\n* Physiologic doses of systemic corticosteroids at doses which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid\r\n* High dose steroid pre-treatment for CT contrast dye allergy is allowed, provided the dose(s) of steroids is(are) given at least 1 week prior to starting the study medicationsXx_NEWLINE_xXImmunosuppressive medication within 14 days prior to day 1 of protocol therapy; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days\r\n* Systemic corticosteroids at physiologic doses of < 10 mg/day of prednisone or equivalentXx_NEWLINE_xXHistory of severe asthma and currently on systemic chronic medications (mild asthma requiring inhaled steroids only is eligible)Xx_NEWLINE_xXFixed or decreasing dose of corticosteroids (or no corticosteroids) >= 7 days prior to registrationXx_NEWLINE_xXConcurrent oral corticosteroid use aside from adrenal replacement, or use of other immunosuppressive agents (ex: infliximab); topical or inhaled steroids will be allowedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid; live attenuated vaccines within 30 days of durvalumab dosing (ie, 30 days prior to the first dose, during treatment with durvalumab and for 30 days post discontinuation of durvalumab); inactivated vaccines, such as the injectable influenza vaccine, are permittedXx_NEWLINE_xXDiagnosis of a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 21 days before the first dose of PD 0360324, with the exceptions of intranasal and inhaled corticosteroids and systemic corticosteroids at physiological doses (defined as not exceeding 10 mg/day of prednisone, or an equivalent dose of over corticosteroid)Xx_NEWLINE_xXIs currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatmentXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agentsXx_NEWLINE_xXPatients requiring systemic corticosteroids (unless patients have had no corticosteroids within 4 weeks prior to start of study)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days prior to first dose of durvalumab; the following are exceptions to this criterion: intranasal, inhaled, topical or local steroid injections (eg. intra-articular injection); steroids as premedication for hypersensitivity reactions; systemic corticosteroid at physiologic doses not to exceed 10mg/day of prednisone or equivalentXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowedXx_NEWLINE_xXConcurrent Therapy \r\n* Patients who are receiving any other anticancer or investigational drug therapy\r\n* Patients requiring systemic treatment with either corticosteroids (greater than dexamethasone 0.75 mg/m^2/day or the equivalent dose of other steroids) or other immunosuppressive medications within 14 days of study drug administration will be excluded; however, patients who require intermittent use of bronchodilators or local steroid injections will not be excluded from the studyXx_NEWLINE_xXUse of systemic corticosteroid therapy (except for replacement doses of glucocorticoid and/or mineralocorticoid for adrenal insufficiency); inhaled or intranasal corticosteroids for allergic or bronchospastic conditions are permittedXx_NEWLINE_xXNo prior therapy is allowed except for the following:\r\n* Short courses of corticosteroid (defined as =< 7 days of corticosteroids within the 4-weeks preceding registration) are allowed\r\n** Participants who have been on corticosteroids chronically (defined as more than 7 days of corticosteroids within the 4-weeks preceding registration or more than 28 days of corticosteroids over the preceding 6 months) are not eligible; previous courses of inhaled corticosteroids of any duration are allowed\r\n* A single dose of intrathecal cytarabine (at the time of the diagnostic lumbar puncture) is allowed prior to registration; if patient has received intrathecal (IT) cytarabine prior to informed consent for protocol treatment, day 1 IT cytarabine should not be administered\r\n* Emergent radiation to the mediastinum or other life-threatening masses is allowed prior to registrationXx_NEWLINE_xXPatients on chronic steroid use or other immunosuppressive agentsXx_NEWLINE_xXUse of systemic corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration, with exception of inhaled or topical steroids.Xx_NEWLINE_xXUse of systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications =< 14 days of registration; Note: Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXCondition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 day of study drug administrationXx_NEWLINE_xXPatients requiring systemic treatment with corticosteroids (> 10mg daily prednisone equivalents) or other immunosuppressive medications =< 14 days prior to first dose of study drug are not eligible\r\n* NOTE: Inhaled and intranasal corticosteroids are permitted; a brief (less than 3 weeks) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by a contact allergen) is permittedXx_NEWLINE_xXPatient must not have received immune suppressants: corticosteroids (for other than allergic reactions and anaphylaxis), cyclosporine or tacrolimus within 7 days of enrollment\r\n* Note: the use of topical and/or inhalational steroids is allowedXx_NEWLINE_xXPatients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (e.g., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to randomization are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the studyXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before step 1 registration, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXTreatment with systemic corticosteroids within 2 weeks prior to the start of the treatment; patients that require inhaled or low-dose corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, mineralocorticoids are allowedXx_NEWLINE_xXPatients who are currently receiving or plan to receive corticosteroids except as described below \r\n* Systemic corticosteroids may be administered for cytoreduction up to 24 hours prior to the start of protocol therapy, as a premedication for InO and as treatment for allergic reactions or for physiologic replacement/stress dosing of hydrocortisone for documented adrenal insufficiency; corticosteroids are not allowed for other indicationsXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXTreatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroidsXx_NEWLINE_xXTREATMENT: Patients requiring chronic treatment with corticosteroids or other immunosuppressive agents are ineligible to receive everolimus (topical or inhaled corticosteroids are allowed)Xx_NEWLINE_xXTreatment with oral/systemic corticosteroids; NOTE: with the exception of topical or inhaled steroidsXx_NEWLINE_xXPatients requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXThere must be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administrationXx_NEWLINE_xXPatients have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXNo oral corticosteroids 3 days before initiating combinations TEW-7197/POM; inhaled corticosteroids are permittedXx_NEWLINE_xXImmunocompromised patients and patients with known immunodeficiency; or receiving systemic steroid therapy or any other immunosuppressive therapy =< 7 days prior to registration; NOTE: inhaled steroids and low-dose corticosteroids are allowedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXPatients with a requirement for steroid treatment or other immunosuppressive treatment: patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXHas had systemic corticosteroids within 2 weeks of the first dose of protocol-related radiation or MK-3475Xx_NEWLINE_xXPatients who are taking immunosuppressive medications that cannot be discontinued (corticosteroids); patients who have discontinued immunosuppressive medications but be at least 1 week post their last doseXx_NEWLINE_xXConcurrent systemic immunosuppressive therapy or steroid therapy with more than 7 consecutive days of steroids within the last 4 weeks except in association with preparative regimen and NK cell infusion-inhaled corticosteroids is permittedXx_NEWLINE_xXConcomitant therapy with any anti-cancer agents, other investigational anti-cancer therapies, or immunosuppressive agents; chronic use of systemic corticosteroidsXx_NEWLINE_xXConcomitant treatment with corticosteroids greater than physiologic doses (used in the management of cancer or non-cancer-related illnesses); topical (if not including the proposed vaccination sites) or inhalational steroids are allowedXx_NEWLINE_xXParticipants that have been receiving the following medications or treatments within the 6 weeks (42 days) prior to consenting:\r\n* Corticosteroids, administered parenterally, orally, or inhaled (inhaled steroids, such as: Advair, Flovent, Azmacort)\r\n* Topical corticosteroids are acceptableXx_NEWLINE_xXAny condition that would prohibit administration of corticosteroidsXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of treatment, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXPatients requiring chronic systemic treatment with steroidsXx_NEWLINE_xXPatients receiving chronic treatment with steroids or another immunosuppressive agent\r\n* Note: topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are allowed; patients with previously treated brain metastases, who are on stable low dose corticosteroids treatment (e.g. dexamethasone 2 mg/day, prednisolone 10 mg/day) for at least 14 days before start of study treatment are eligibleXx_NEWLINE_xXCurrent treatment with systemic steroid therapy (inhaled/topical steroids are acceptable); systemic corticosteroids must be discontinued for at least 30 days prior to first CYT107 injectionXx_NEWLINE_xXPatients who have received any of the following concomitant therapy: interleukin (IL)-2, interferon; immunosuppressive agents; or chronic use of systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses)Xx_NEWLINE_xXImmunosuppressive treatment that cannot be discontinued prior to study entry and for the duration of the study. Immunosuppressive treatment should be discontinued for at least 1 week prior to start of the administration of CPI-0610. Oral prednisone at a dose of 10mg or less per day is allowed, as are other oral corticosteroids given at glucocorticoid-equivalent doses. Topical, nasal and inhaled corticosteroids are also allowedXx_NEWLINE_xXPatient is currently receiving increasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent, as chronic administration of corticosteroids (> 5 days) can induce cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4); see also section “concomitant medication”; the following uses of corticosteroids are permitted: single doses; e.g. with standard premedication for infusions; topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g., intra-articular); patients may take 10mg or less (or equivalent) of oral prednisone dailyXx_NEWLINE_xXThe following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXAny use of systemic corticosteroids in the prior 4 weeksXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXConcurrent use of systemic corticosteroids (nasal corticosteroids, inhaled steroids, adrenal replacement steroids, and topical steroids are allowed)Xx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids (=< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment)\r\n* The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agentXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXThere is no limitation to prior treatments with local, regional, topical or systemic agents, except for prior systemic treatment with 5-fluorouracil or prodrugs thereof; prior topical treatment with 5-fluorouracil is permitted; patients who are on chronic daily doses of prednisone of greater than 10 mg are excluded; there is no restriction on timing of last treatments as long as patients have recovered from all expected toxicities and at least 21 days have passed since last administrationXx_NEWLINE_xXPatients requiring treatment with corticosteroids are eligibleXx_NEWLINE_xXOngoing requirement for an immunosuppressive treatment, including the use of glucocorticoids or cyclosporine, or with a history of chronic use of any such medication within the last 4 weeks before enrolment; patients are excluded if they have any concurrent medical condition that requires the use of systemic steroids (the use of inhaled or topical steroids is permitted)Xx_NEWLINE_xXConcurrent therapy with systemic corticosteroids or other immunosuppressive medicationsXx_NEWLINE_xXConcurrent use of systemic steroids, except for physiologic doses of systemic steroids for replacement or local (topical, nasal, or inhaled) steroid use; limited doses of systemic steroids to prevent intravenous (IV) contrast, allergic reaction, or anaphylaxis (in patients who have known contrast allergies) are allowed; although topical steroids are allowed, steroid eye-drops are contraindicatedXx_NEWLINE_xXConditions that would prohibit administration of corticosteroidsXx_NEWLINE_xXStudy participants who have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXConcurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical, nasal, eye drops or inhaled) steroid use; limited doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent IV contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowedXx_NEWLINE_xXTreatment with any of the following medications or interventions within 28 days of registration:\r\n* Systematic corticosteroids; use of inhaled, intranasal, and topical steroids is acceptable\r\n* Any other systemic therapy for prostate cancer (except for medical castration)Xx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids (more than 20 mg/day prednisone equivalent, see inclusion criteria) or another immunosuppressive agent; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent are not eligible to participate in this study; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXPatients needing chronic, immunosuppressive systemic steroids are excludedXx_NEWLINE_xXImmunosuppressive medications including systemic corticosteroids unless used for adrenal replacement, appetite stimulation, acute therapy for asthma or bronchitis exacerbation (=< 2 weeks), or antiemesisXx_NEWLINE_xXPatients needing chronic, immunosuppressive systemic steroids are excludedXx_NEWLINE_xXUse of systemic corticosteroids or other immunosuppressive agents within the previous 4 weeks of study enrollmentXx_NEWLINE_xXPatients receiving chronic treatment with steroids or another immunosuppressive agent; note: topical applications (e.g. for rash), inhaled sprays (e.g. for obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are allowed; patients with previously treated brain metastases, who are on stable low dose corticosteroids treatment (e.g. dexamethasone 2 mg/day, predisolone 10 mg/day) for at least 14 days before start of study treatment are eligibleXx_NEWLINE_xXPatients who require systemic corticosteroid or other immunosuppressive therapy for GVHD; immunosuppressive therapy must be stopped at least 28 days prior to protocol course 1 day 1 (C1D1); steroids for physiologic replacement, for ALL maintenance or topical agents and/or inhaled corticosteroids are permittedXx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids (of more than 4 mg/day or equivalent of dexamethasone; doses of dexamethasone of up to 8 mg/day may be administered for less than 2 weeks) or another immunosuppressive agent; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXPatients taking systemic corticosteroidsXx_NEWLINE_xXConcurrent medical condition requiring the use of immunosuppressive medications or immunosuppressive doses of systemic or absorbable topical corticosteroidsXx_NEWLINE_xXConcurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroidsXx_NEWLINE_xXPatients must not require chronic treatment with systemic steroids (inhaled steroids are allowed) or other immunosuppressive agentsXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administrationXx_NEWLINE_xXUse of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to first dose of study treatment.Xx_NEWLINE_xXSystemic corticosteroids at doses greater than 40mg hydrocortisone daily or equivalent for any reason other than treatment of prostate cancer (PCa) within the previous 6 monthsXx_NEWLINE_xXSystemic immunosuppressive therapy for any reasonXx_NEWLINE_xXImmunosuppressive regimens involving systemic corticosteroids within 14 days before the first dose of study treatment.Xx_NEWLINE_xXHas received more than 1 systemic treatment in addition to corticosteroids for acute GVHD.Xx_NEWLINE_xXPatients NOT receiving systemic immune suppressive therapy for treatment of active GVHD (topical skin and GI corticosteroids are allowed).Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications within 2 weeks prior to first dosing (inhaled corticosteroids and mineralocorticoids are allowed).Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatmentXx_NEWLINE_xXConcurrent, recent (? 4 weeks ago) or anticipated treatment with systemic corticosteroids at any dose, orXx_NEWLINE_xXSubject is currently receiving or requires treatment with immunosuppressive agents or immunosuppressive doses of systemic corticosteroids (unless used to treat drug-related adverse events).Topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption), and some uses of systemic corticosteroids are permitted as per Section 9.1.Xx_NEWLINE_xXSubject is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug or who have not fully recovered from side effects of such treatment; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agents except (i) inhaled or topical steroids or replacement dose corticosteroids equivalent to ? 10 mg prednisone and (ii) patients receiving physiological doses of hydrocortisone for adrenal insufficiencyXx_NEWLINE_xXPatients must not be receiving chronic, systemic treatment with corticosteroids or other immunosuppressive agent; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXPatients must not have received any immunosuppressive medication within 28 days prior to sub-study registration and must not be planning to receive any such agents while on protocol treatment; however, intranasal and inhaled corticosteroids or systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent are allowedXx_NEWLINE_xXPatients must not have received any immunosuppressive medication within 28 days prior to RE-TREATMENT registration and must not be planning to receive any such agents while on protocol treatment; however, intranasal and inhaled corticosteroids or systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent are allowedXx_NEWLINE_xXIntranasal, inhaled, topical or local steroid injections (eg, intra-articular injection);Xx_NEWLINE_xXIs on chronic systemic steroids.Xx_NEWLINE_xXConcurrent, recent (? 4 weeks ago) or anticipated treatment with systemic corticosteroids at any dose, orXx_NEWLINE_xXHave had any chemotherapy or systemic corticosteroids within 2 weeks of study entry.Xx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trialXx_NEWLINE_xXIntranasal, inhaled, topical, or local steroid injections (eg, intra-articular injection)Xx_NEWLINE_xXOngoing systemic immunosuppressive therapy other than corticosteroids.Xx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids within =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment; NOTE: the following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXPatients on immunosuppressive therapy including systemic corticosteroids.Xx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) at the time of initiation of study drug, or anticipated requirement for systemic immunosuppressive medications during the studyXx_NEWLINE_xXPatients who have received corticosteroids within 7 days prior registration are not eligible, UNLESS the patient has been taking a continuous dose of no more than 15 mg/day of prednisone for at least 1 month prior; NOTE: low dose steroid use for control of nausea and vomiting will be allowed; topical steroid use and inhaled steroids are also permittedXx_NEWLINE_xXConcurrent, recent (? 4 weeks ago) or anticipated treatment with systemic corticosteroids at any dose, orXx_NEWLINE_xXTreatment with systemic immunosuppressive medications, including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) agents within 2 weeks prior to Cycle 1, Day 1; inhaled corticosteroids and mineralocorticoids are allowedXx_NEWLINE_xXUse of systemic corticosteroid.Xx_NEWLINE_xXConcurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of trial treatment. Short-term administration of systemic steroids (that is, for allergic reactions or the management of immune-related adverse events [irAE]) while on study is allowed. Also, subjects requiring hormone replacement with corticosteroids for adrenal insufficiency are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses <= 10 mg or equivalent prednisone per day. Note: Subjects receiving bisphosphonate or denosumab are eligible.Xx_NEWLINE_xXNo concomitant therapy with any of the following: interleukin (IL) 2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids; must have been discontinued >= 4 weeks prior to randomizationXx_NEWLINE_xXPatients are ineligible if they have any concurrent medical condition requiring the use of systemic steroids; (use of inhaled or topical steroids is acceptable)Xx_NEWLINE_xXUse of systemic steroid therapy within 28 days of study screening; patients on inhaled or topical steroids are eligibleXx_NEWLINE_xXTreatment with systemic immunosuppressive medicationsXx_NEWLINE_xXConcomitant medication that may interfere with study results; e.g. immunosuppressive agents other than corticosteroids;Xx_NEWLINE_xXInhaled steroids are permittedXx_NEWLINE_xXImmunosuppressive treatment that cannot be discontinued both prior to study entry and for the duration of the study. Oral prednisone at a dose of 10 mg or less per day is allowed, as are other oral corticosteroids given at glucocorticoid-equivalent doses. Topical, nasal and inhaled corticosteroids are also allowed.Xx_NEWLINE_xXTreatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-· agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study, with the following exceptions: patients who received low-dose immunosuppressant medication are eligible for the study; patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the studyXx_NEWLINE_xXConcurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroidsXx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to enrollmentXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736 with the exceptions of intranasal and inhaled corticosteroids, or systemic corticosteroids in Cohort CXx_NEWLINE_xXAny condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug; inhaled steroids and adrenal replacement steroids doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXDaily administration of systemic immunosuppressive therapy or corticosteroids (except in physiological doses for hormone deficiency) during the previous 30 days.Xx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXTreatment with per oral systemic corticosteroids exceeding 10mg/day within seven (7) days before Screening until nephrectomy (inhaled, intranasal and local steroids accepted irrespective of dose)Xx_NEWLINE_xXUse of systemic immunosuppressive drugsXx_NEWLINE_xXSubjects should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration.Xx_NEWLINE_xXOngoing immunosuppressive therapy, including cyclosporine and tacrolimus; patients who are on high dose steroid; Note: Subjects may be using systemic corticosteroids (daily doses =< 10 mg of prednisone or equivalent) or topical or inhaled corticosteroidsXx_NEWLINE_xXConcurrent treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (exception: inhaled or topically applied steroids, and acute and chronic standard dose NSAIDs, are permitted). Use of a short course (i.e., ? 1 day) of a glucocorticoid is acceptable to prevent a reaction to the IV contrast used for CT scans.Xx_NEWLINE_xXPatients receiving concomitant immunosuppressive agents or chronic corticosteroids use at the time of study entry except for control of brain metastases, topical applications, inhaled sprays, eye drops or local injectionsXx_NEWLINE_xXReceipt of corticosteroids within 7 days prior to the first dose of study treatment, unless patient has been taking a continuous dose of no more than 15 mg/day of prednisone for at least 1 month prior to first dose of study treatment; low dose steroid use for the control of nausea and vomiting will be allowed; topical steroid use is permitted; inhaled steroids are permittedXx_NEWLINE_xXPatient is currently receiving increasing or chronic treatment (> 10 days) with corticosteroids or another immunosuppressive agent; the following uses of corticosteroids are permitted: single dose, topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXConcurrent use of systemic steroids, through 72 hours post the last RNA CART19 infusion; recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary\r\n* Therapeutic doses of steroids must be stopped > 72 hours prior to CTL019 infusion; however, the following physiological replacement doses of steroids are allowed: < 6-12 mg/m^2/day hydrocortisone or equivalentXx_NEWLINE_xXPatients receiving chronic treatment with systemic steroids or another immunosuppressive agent.Xx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent with the following exceptions:\r\n* Intermittent steroids (not to exceed 4 mg every day) may be used on an as-needed basis (e.g. treatment for chemotherapy-related nausea, anorexia and fatigue)\r\n* Patients on physiologic replacement doses of steroids due to adrenal insufficiency for any reason may remain on these medications\r\n* Topical, inhaled or intra-articular corticosteroidsXx_NEWLINE_xXPotential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 4 weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)Xx_NEWLINE_xXUse of corticosteroids or other immunosuppressive medicationsXx_NEWLINE_xXNeurologically stable defined as receiving no, stable, or tapering doses of corticosteroids for >= 5 days prior to drug dosing; treatment with corticosteroids during the study is allowed, and can be adjusted by the investigator during the study; changes in steroid dose are incorporated into the Revised Assessment in Neuro-Oncology (RANO) imaging criteriaXx_NEWLINE_xXLong-term use of systemic corticosteroids; patients with replacement steroids and not immunosuppressive steroids may enroll in the studyXx_NEWLINE_xXSystemic (oral or parenteral) corticosteroids within 14 days of study entryXx_NEWLINE_xXPatients must have been off pharmacologic doses of systemic steroids for at least 7 days prior to enrollment; patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible; the only exception is for patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration in order to avoid allergic transfusion reactions; the use of conventional doses of inhaled steroids for the treatment of asthma is permitted, as is the use of physiologic doses of steroids for patients with known adrenal insufficiencyXx_NEWLINE_xXSubjects receiving chronic, systemic treatment with corticosteroids equivalent to > 20 mg of prednisone per day; subjects receiving replacement for adrenal insufficiency will be allowed on the study; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXCurrent use of systemic corticosteroidsXx_NEWLINE_xXA requirement for daily systemic corticosteroids for any reason; or other immunosuppressive or immunomodulatory agents; topical, nasal or physiologic corticosteroids are to be permittedXx_NEWLINE_xXPatients receiving corticosteroids are not eligible; patients must have been off corticosteroids for 7 days prior to start of chemotherapyXx_NEWLINE_xXPotential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 4 weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)Xx_NEWLINE_xXActive autoimmune disease or any condition requiring systemic treatment with either corticosteroids (> 10 mg daily of prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1 \r\n* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids or mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXCondition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to study therapy administration. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.Xx_NEWLINE_xXHave a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 15 days prior to the first dose of study treatment (nivolumab). Inhaled or topical steroids and adrenal replacement doses (? 10 mg daily prednisone equivalents) are permitted in the absence of active autoimmune disease.Xx_NEWLINE_xXUse of immunosuppressive therapy within 28 days of starting study treatment. Immunosuppressive therapy includes but is not limited to cyclosporine A, tacrolimus, or high-dose corticosteroids. Subjects receiving corticosteroids must be at a dose level ? 10 mg/day within 7 days of initiating study treatment.Xx_NEWLINE_xXPatients with adrenal insufficiency or patients currently requiring chronic, systemic corticosteroid therapy at any dose for longer than 2 weeks. Local steroid therapies (eg, otic, ophthalmic, intraarticular, or inhaled medications) are acceptableXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXIf receiving corticosteroids, patients must be on a stable or decreasing dose of corticosteroids for ? 5 days prior to baseline MRI.Xx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.Xx_NEWLINE_xXPatients will be excluded if they have a condition requiring systemic treatment with either corticosteroids (>10mg/day prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence or active autoimmune disease.Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXPatients are excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration, with the exception of a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen); participants are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption)Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) =< 14 days prior to randomization; exception: patients who have received acute, low-dose, systemic immunosuppressant medications (e.g. a one-time dose of dexamethasone for nausea) are eligible; the use of inhaled corticosteroids and mineral-corticoids (e.g. fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days prior to first dose of durvalumab; the following are exceptions to this criterion: intranasal, inhaled, topical or local steroid injections (eg. intra-articular injection); steroids as premedication for hypersensitivity reactions; systemic corticosteroid at physiologic doses not to exceed 10 mg/day of prednisone or equivalent; (NOTE: If systemic corticosteroids are part of the treatment regimen for the indication under study, the systemic corticosteroid is permitted)Xx_NEWLINE_xXActive or history of concomitant therapy with any of the following: interleukin (IL)2, interferon, or other non-study immunotherapy regimens, immunosuppressive agents, other investigational therapies, or chronic use of systemic corticosteroids (inhaled and topical steroids at physiological doses, not to exceed 10 mg/day prednisone or an equivalent, are permitted)Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled, topical intranasal or intro-ocular steroids, and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid; steroid pre-medication for CT scan contrast or study drug, is allowable, regardless of doseXx_NEWLINE_xXPatient is currently receiving increasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent; the following uses of corticosteroids are permitted: single doses; e.g. with standard premedication for taxanes; topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g., intra-articular); patients requiring chronic therapy with steroids may take no more than 10 mg daily of prednisone or equivalentXx_NEWLINE_xXPatients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXTreatment with systemic immunosuppressive medications, including but not limited to prednisone, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to D1C1Xx_NEWLINE_xXPatients are ineligible who have any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug; Note: inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; a brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permittedXx_NEWLINE_xXChronic administration (defined as daily or every other day for continued use > 14 days) of corticosteroids deemed systemic by investigator within 28 days before the first planned dose of PROSTVAC; use of inhaled steroids, nasal sprays, intra-articular injections and topical creams for small body areas is allowedXx_NEWLINE_xXConcurrent or planned concurrent treatment with systemic high dose (immunosuppressive) corticosteroids or treatment with systemic corticosteroids within 4 weeks of baselineXx_NEWLINE_xXMedical conditions (aside from newly-diagnosed brain metastases) for which the chronic use of corticosteroids or other immunosuppressive medications are indicated; Note: inhaled and topical steroids are permittedXx_NEWLINE_xXUse of immunosuppressive medications within 14 days before the first dose of study drug; the following are exceptions to this criterion: intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra articular injection); systemic corticosteroids at physiological doses not to exceed 10mg/day of prednisone or its equivalent; steroids as premedication for hypersensitivity reactions (e.g. computed tomography [CT] scan premedication)Xx_NEWLINE_xXSystemic corticosteroid therapy for any reason, including replacement therapy for hypoadrenalism. Patients receiving inhaled or topical corticosteroids may participate (if therapy is < 5 days and is limited to systemic steroids as antiemetics).Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to cycle 1, day 1 \r\n*Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n*The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXInitiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers) within 1 week before administration of the first dose of study drug (patients already receiving erythropoietin on a chronic basis for >= 4 weeks are eligible)Xx_NEWLINE_xXPatients who have received oral or parenteral corticosteroids within 2 weeks of study entry or who have a clinical requirement for ongoing systemic immunosuppressive therapy not related to chemotherapy administration.Xx_NEWLINE_xXPatients on immunosuppressants, systemic corticosteroids, or any other investigational product.Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of MEDI4736 (excluding intranasal, inhaled, topical steroids, or local steroid injections)Xx_NEWLINE_xXUse of corticosteroids or other immunosuppressive medicationsXx_NEWLINE_xXSystemic steroids should be stopped 2 weeks before the start of treatment; topical and inhaled steroids are allowedXx_NEWLINE_xXPatients taking immunosuppressive medicationsXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 day of study drug administrationXx_NEWLINE_xXIs dependent on, currently or has received within the past 4 weeks corticosteroids (hormone replacement therapy, topical corticosteroids and occasional inhaled corticosteroids are allowed).Xx_NEWLINE_xXOral or parenteral immunosuppressive agents (not topical or inhaled steroids) at any time during study participation or within 6 months prior to enrolment.Xx_NEWLINE_xXPatients who require pharmacological or replacement doses of systemic corticosteroids or who have received systemic corticosteroids within 30 days of study entry; use of topical, inhaled or ophthalmic steroids is permitted.Xx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXDiagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy (excludes inhaled corticosteroids) within 7 days of first dose of study drugXx_NEWLINE_xXCondition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXHas received systemic immunosuppressive treatments, aside from systemic corticosteroids as described below (such as methotrexate, chloroquine, azathioprine, etc) within six months of start of study drugXx_NEWLINE_xXCurrent or recent (=< 4 weeks) use of immunosuppressive medications including systemic (inhaled, oral, or intravenous [IV]) corticosteroids; Note: use of corticosteroids in doses not exceeding those used for adrenal replacement is acceptableXx_NEWLINE_xXBrain metastases are allowed if they have been adequately treated with radiotherapy or surgery and have been stable for at least three months prior to registration; eligible subjects should be neurologically asymptomatic; there is no magnetic resonance imaging (MRI) evidence of progression for a minimum of 4 weeks after treatment is complete and within 28 days prior to the first dose of nivolumab administration; there must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administrationXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agents; note: topical or inhaled corticosteroids are allowedXx_NEWLINE_xXPatients must not be receiving chronic, systemic treatment with corticosteroids or other immunosuppressive agent; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXPatients receiving chronic treatment with steroids or another immunosuppressive agent\r\n* Note: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are allowed; patients with previously treated brain metastases, who are on stable low dose corticosteroid treatment (e,g dexamethasone 2 mg/day, prednisolone 10 mg/day) for at least 14 days before start of study treatment are eligibleXx_NEWLINE_xXReceipt of corticosteroids within 7 days prior to the first dose of study treatment, unless patient has been taking a continuous dose of no more than 15 mg/day of prednisone for at least 1 month prior to first dose of study treatment; low dose steroid use for the control of nausea and vomiting will be allowed; topical steroid use is permitted; inhaled steroids are permittedXx_NEWLINE_xXSystemic corticosteroids use =< 2 weeks, regardless of indication; note: patients who are on inhaled corticosteroids are eligibleXx_NEWLINE_xXOngoing immunosuppressive therapy, including systemic or enteric corticosteroids for treatment of CLL or other conditions. Note: Subjects may be using topical or inhaled corticosteroids as therapy for comorbid conditions.Xx_NEWLINE_xXConcurrent medical condition requiring the use of immunosuppressive medications or immunosuppressive doses of systemic or absorbable topical corticosteroids (doses greater than 10 mg/day prednisone or equivalent); inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued; non-absorbed intra-articular steroid injections are allowed; the exception to the use of steroids is the treatment of serious adverse events (SAEs) such as pneumonitis and the prevention of emesisXx_NEWLINE_xXAny condition requiring concurrent systemic immunosuppressive therapyXx_NEWLINE_xXTreatment with any of the following medications or interventions concomitantly or within 28 days of starting ipilimumab: a) systemic corticosteroids; use of inhaled, intranasal, intra-articular and topical steroids is acceptable, as is a short course (i.e. =< 1 day) of corticosteroids to prevent a reaction to the IV contrast used for CT scans; b) external beam radiation therapy or major surgery requiring general anesthetic; c) any systemic therapy for prostate cancer (with the exception of bisphosphonates and receptor activator of nuclear factor kappa [RANK]-ligand inhibitors for bone metastases which are allowed) including chemotherapy, secondary hormonal therapies, (such as megestrol acetate, diethylstilbestrol, ketoconazole, abiraterone, enzalutamide) and non-steroidal anti-androgens (such as bicalutamide, flutamide or nilutamide); d) immune modulators, cytokines or vaccines for the management of cancer or non-cancer-related illnesses; e) any non-oncology vaccine therapy used for prevention of infectious diseases (for up to one month before any dose of ipilimumab); f) any other investigational productXx_NEWLINE_xXImmunosuppressive therapy (excluding topical steroids) for any other condition =< 4 weeks prior to registrationXx_NEWLINE_xXConcomitant therapy with immune-suppressants or chronic use of systemic corticosteroidsXx_NEWLINE_xXChronic treatment with systemic steroids or another immunosuppressive agent; subjects with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessaryXx_NEWLINE_xXPatients receiving concurrent corticosteroids for reason(s) other than for physiologic maintenance treatment; patients should otherwise discontinue corticosteroids prior to registration to studyXx_NEWLINE_xXConcurrent maintenance corticosteroids;Xx_NEWLINE_xXDependence on corticosteroids\r\n* Defined as doses of corticosteroids of greater than or equal to 5 mg/day of prednisone or equivalent doses of other corticosteroids\r\n* Note: topical and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowedXx_NEWLINE_xXImmunosuppressive diseaseXx_NEWLINE_xXNo previous use of corticosteroids for autoimmune complications that have developed since the initial diagnosis of CLL; prior use of corticosteroids for reasons other than treatment of autoimmune complications is allowedXx_NEWLINE_xXHistory of long-term use of corticosteroids or concurrent short-term use of corticosteroids is not allowed; short-term corticosteroid use must be discontinued at least 2 weeks prior to study treatmentXx_NEWLINE_xXSubjects taking systemic (parentally or orally) corticosteroid therapy for any reason, including replacement therapy for hypoadrenalism, are not eligible. Topical steroids are acceptable as are intranasal steroids.Xx_NEWLINE_xXCOHORT A: Concomitant or prior therapy with any of the following: aldesleukin (IL-2), interferon, or other non-study immunotherapy regimens; immunosuppressive agents; or chronic use of systemic corticosteroids within 6 weeks of study entryXx_NEWLINE_xXCOHORT B: Concomitant or prior therapy with any of the following: IL-2, interferon, or other non-study immunotherapy regimens; immunosuppressive agents; or chronic use of systemic corticosteroids within 6 weeks of study entryXx_NEWLINE_xXPatients receiving current treatment with corticosteroids or another immunosuppressive. Topical or inhaled corticosteroids are allowed.Xx_NEWLINE_xXChronic system corticosteroids for any reason (inhaled corticosteroids are allowed); pre-medication for chemotherapy is acceptableXx_NEWLINE_xXChronic immunosuppressive therapies, including systemic corticosteroidsXx_NEWLINE_xXFixed or decreasing dose of corticosteroids (or no corticosteroids) >= 7 days prior to registrationXx_NEWLINE_xXPatients who have received any of the following concomitant therapy: interleukin (IL)-2, interferon or other non-study immunotherapy regimens; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses) within 1 week prior to first dose; Note: systemic steroid therapy allowed for subjects with primary brain tumors as long as =< dexamethasone 4 mg or its steroid equivalentXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n*Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n*The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXCurrent use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)Xx_NEWLINE_xXConcomitant use of the following medications\r\n* Any investigational anticancer therapy\r\n* Any concurrent chemotherapy, immunotherapy, or biologic therapy; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable\r\n* Immunosuppressive medications including, but not limited to systemic corticosteroids (> 10 mg/day prednisone or equivalent), methotrexate, azathioprine, and tumor necrosis factor alpha (TNF-alpha) blockers; use of immunosuppressive medications for the management of investigational product-related adverse event (AE)s, in subjects with contrast allergies is acceptable; in addition, use of inhaled and intranasal corticosteroids is permittedXx_NEWLINE_xXUse of more than low dose corticosteroids (e.g., prednisone up to but no more than 10 mg PO QD or its equivalent) for symptom management and comorbid conditions, except for the following:\r\n* Topical applications (e.g. rash)\r\n* Inhaled sprays (e.g. obstructive airways diseases)\r\n* Eye drops or local injections (e.g. intra-articular)\r\n* Joint injections (e.g. arthritis)\r\nDoses of corticosteroid should be stable for at least 7 days prior to registrationXx_NEWLINE_xXBrain metastases that are symptomatic or untreated or not stable for >= 3 months (must be documented by imaging) or requiring corticosteroids; subjects on a stable dose of corticosteroids > 1 month or who have been off corticosteroids for at least 2 weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP) medical monitor; subjects must also be off enzyme-inducing anticonvulsants for > 4 weeksXx_NEWLINE_xXAny prior systemic antimyeloma therapy except oral steroids (dexamethasone up to a total dose of 160 mg or equivalent within 14 days prior to the first dose of study treatment). Use of topical or inhaled steroids is acceptableXx_NEWLINE_xXPatients treatment with systemic steroids or another immunosuppressive agent; patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessaryXx_NEWLINE_xXChronic administration (defined as daily or every other day for continued use > 14 days) of corticosteroids deemed systemic by investigator within 28 days before the first planned dose of PSA-TRICOM; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowedXx_NEWLINE_xXPatients who are immunocompromised as listed as follows:\r\n* Human immunodeficiency virus positivity\r\n* Chronic administration (defined as daily or every other day for continued use > 14 days) of systemic corticosteroids (including steroid eye drops) or other immune suppressive drugs, within 28 days before the first planned dose of PSA-TRICOM; nasal, or inhaled steroid, and topical steroid creams for small body areas are not excluded\r\n* Patients who have undergone allogeneic peripheral stem cell transplantation, or solid organ transplantation requiring immunosuppression \r\n* History of splenectomyXx_NEWLINE_xXCurrently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)Xx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatmentXx_NEWLINE_xXNo concurrent condition resulting in immune compromise, including chronic treatment with corticosteroids or other immunosuppressive agentsXx_NEWLINE_xXNo systemic corticosteroids or immunosuppressive drugs (topical acceptable); replacement steroids for adrenal insufficiency are not excludedXx_NEWLINE_xXSubjects taking chronic systemic corticosteroid therapy for any reason are not eligible. Subjects may receive steroids as prophylactic anti-emetics per the FOLFIRINOX or gemcitabine/nab-paclitaxel regimen. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require chronic systemic corticosteroids after beginning treatment, will be removed from study.Xx_NEWLINE_xXTreatment with corticosteroids within 2 weeksXx_NEWLINE_xXA requirement for chronic systemic immunosuppressive therapy for any reasonXx_NEWLINE_xXCurrent treatment with systemic steroid therapy (inhaled/topical steroids are acceptable). Systemic corticosteroids must be discontinued for at least 4 weeks prior to first treatment.Xx_NEWLINE_xXContraindication to corticosteroidsXx_NEWLINE_xXPatients receiving chronic treatment with steroids or another immunosuppressive agent other than specified above\r\n* Note: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are allowed; patients with previously treated brain metastases, who are on stable low dose corticosteroids treatment (eg. dexamethasone 2 mg/day, prednisolone 10 mg/day) for at least 14 days before start of study treatment are eligibleXx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXConcurrent condition resulting in immune compromise, including chronic treatment with corticosteroids or other immunosuppressive agentsXx_NEWLINE_xXSubjects taking systemic corticosteroid therapy for any reason including replacement therapy for hypoadrenalism, are not eligible. Subjects receiving inhaled or topical corticosteroids are eligible. Decadron treatment with docetaxel is acceptable.Xx_NEWLINE_xXConcurrent use of systemic steroids; recent or current use of inhaled steroids is not exclusionaryXx_NEWLINE_xXPatients with uncontrolled brain metastases; patients who are on a stable dose of corticosteroids for more than 1 month or off corticosteroids for 2 weeks prior to study enrollment can be enrolled; enzyme-inducing anti-epileptic drugs are not permittedXx_NEWLINE_xXSubjects with condition requiring systemic treatment with either corticosteroids (> 10mg daily prednisone/equivalent) or other immunosuppressive medications within 14 days of study drug administrationXx_NEWLINE_xXTreatment with any of the following medications within 28 days of registration, or while on study, is prohibited:\r\n* Systemic corticosteroids (at doses over the equivalent of 1 mg prednisone daily); inhaled, intranasal or topical corticosteroids are acceptable\r\n* Prostate cancer (PC)-SPES\r\n* Saw palmetto\r\n* Megestrol\r\n* Ketoconazole\r\n* 5-alpha-reductase inhibitors-patients already taking 5-alpha-reductase inhibitors prior to 28 days prior to registration may stay on these agents throughout the course of therapy, but these should not be started while patients are on study\r\n* Diethyl stilbestrol\r\n* Abiraterone\r\n* Any other hormonal agent or supplement being used with the intent of cancer treatmentXx_NEWLINE_xXWithin 4 weeks of treatment initiation (day 0), have received treatment with:\r\n* Local radiation therapy\r\n* UVB therapy\r\n* PUVA\r\n* Any topical chemotherapy\r\n* Photopheresis\r\n* Systemic retinoids, corticosteroids, immune response modifiers (other than imiquimod), interferon inducers, chemotherapeutic agents, biologic agents including interferon\r\n* Topical corticosteroids or retinoidsXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomizationXx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent(Topical or inhaled corticosteroids are allowed)Xx_NEWLINE_xXPatients receiving immunosuppressive treatment as well as corticosteroids which cannot be discontinued at least 4 weeks before dosing.Xx_NEWLINE_xXLong term concurrent medications and/or treatments Not Allowed: \r\n* Corticosteroids, chemotherapy, cyclosporin A; short term (approximately 1 week) use of topical, low-dose or inhaled steroids may be allowed at the discretion of the investigator; injectables not allowedXx_NEWLINE_xXChronic use of corticosteroidsXx_NEWLINE_xXConcomitant therapy with any of the following: interleukin (IL) 2 or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids; unless discontinued >= 4 weeks; a history of occasional use of steroid inhalers is allowedXx_NEWLINE_xXUse of chronic corticosteroids, hydroxyurea, or immunomodulating agents (e.g. interleukin-2, interferon-alpha or gamma, granulocyte colony stimulating factors, etc.) within 30 days prior to study entry. NOTE: Recent or current use of inhaled steroids is not exclusionary. If subjects are prescribed a brief course of oral corticosteroids, the use should be limited to less than 7 days. Use of steroids before apheresis and immune assessment blood draws should be discouraged as it will affect white blood cell function.Xx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXLong-term use of systemic corticosteroidsXx_NEWLINE_xXConcomitant therapy with any of the following: interleukin (IL)2, interferon, or other non-study immunotherapy regimens; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroidsXx_NEWLINE_xXPatients receiving chronic systemic treatment with corticosteroids (dose of >= 10 mg/day methylprednisone equivalent) or another immunosuppressive agent; inhaled and topical steroids are acceptableXx_NEWLINE_xXConcomitant corticosteroid use for systemic or topical treatment of skin disease is not allowed except a dose of steroid of no more than 20 mg of prednisone or its equivalence is allowed for asthma, chronic obstructive pulmonary disease (COPD), or inflammatory bowel disease (IBD); stable use of topical corticosteroids of mid-potency will be allowed for patients with erythroderma-Sezary syndrome (T4) and tumor stage (T3) with intense pruritusXx_NEWLINE_xXPatients requiring chronic immunosuppressive therapy (including corticosteroids) for any medical conditionXx_NEWLINE_xXPatients currently receiving chronic systemic treatment with steroids or another immunosuppressive agent; NOTE: this restriction regarding choice of glucocorticoid does not apply should patient need < 2 week course of glucocorticoid for treatment of noninfectious pneumonitis during study, or if ARM C patient with brain metastases treated with glucocorticoid is enrolled; topical applications (e.g., rash), inhaled sprays, eye drops or local injections of steroids are allowedXx_NEWLINE_xXChronic treatment with systemic steroids or another immunosuppressive agentXx_NEWLINE_xXPatients with a diagnosis of immunodeficiency, or who are dependent on or have received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment with the exception of topical corticosteroids and occasional inhaled corticosteroids, as indicatedXx_NEWLINE_xXRequire concurrent treatment with immunosuppressive agents (other than corticosteroids prescribed for a short course of therapy)Xx_NEWLINE_xXChronic treatment with systemic corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXEXPANSION COHORT ONLY: Chronic treatment with systemic corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXAny syndrome that requires systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days of study drug administration; of note: inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents, are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXCurrent or prior use of immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) or other immunosuppressive medications within 2 weeks of study drug administration; NOTE: subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)Xx_NEWLINE_xXCurrent use of immunosuppressive medication, except for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab (MEDI4736) or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or any corticosteroid for less than 4 consecutive daysXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1 \r\n* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXSubjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs 14 days before initiation of study treatment. Steroids with no or minimal systemic effect (topical, inhalation) are allowed. Note: Subjects receiving bisphosphonate or denosumab are eligible provided that treatment was initiated ?14 days before first dose of AGEN2034. Note: Use of inhaled or topical corticosteroid is permitted. Note: Steroid pre-medication for radiographic imaging for dye allergies is permitted.Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or durvalumab and tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid; patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone for nausea or steroids as CT scan contrast premedication) may be enrolledXx_NEWLINE_xXSubjects who have used systemic corticosteroids or other immunosuppressants for any condition within 14 days of randomization. Inhaled or topical steroids are permitted.Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic (oral or iv) corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXUse of systemic steroids within 7 days before the first dose of MEDI-551 (inhaled and topical corticosteroids are permitted). Subjects may take replacement doses of steroids (defined as ? 30 mg/day hydrocortisone or the equivalent) if on a stable dose for at least 2 weeks prior to the first dose of MEDI-551. This does not include required steroid prophylaxis prior to the first infusion of MEDI-551Xx_NEWLINE_xXNo concomitant therapy with steroids (replacement doses of steroids are allowed)Xx_NEWLINE_xXNo concurrent use of systemic steroids, except for local (topical, nasal, or inhaled) steroid use (replacement doses of steroids allowed)Xx_NEWLINE_xXSupraphysiologic doses of corticosteroids within 3 weeksXx_NEWLINE_xXPatients receiving corticosteroids at the time of the first vaccine, with the exception of nasal or inhaled steroid, at a dose above physiologic levels will be removed and replaced; for the purposes of this study, physiologic dose will be defined as < 2 mg of dexamethasone/day; once vaccinations have been initiated, if patients subsequently require increased steroids, they will still be permitted to remain on the study, but every effort will be made to minimize steroid requirementsXx_NEWLINE_xXSubjects with a medical condition requiring chronic systemic corticosteroidsXx_NEWLINE_xXPatients must not be receiving chronic systemic corticosteroids at doses greater than physiologic dosing (inhaled corticosteroids acceptable).Xx_NEWLINE_xXUse of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to first dose of study treatment.Xx_NEWLINE_xXOngoing systemic immunosuppressive therapy other than corticosteroidsXx_NEWLINE_xXSubjects must be receiving systemic corticosteroids.Xx_NEWLINE_xXSubjects requiring chronic use of immunosuppressive agents (eg, methotrexate, cyclosporine, corticosteroids)Xx_NEWLINE_xXOngoing immunosuppressive therapy, including systemic or enteric corticosteroids (can be using topical or inhaled corticosteroids).Xx_NEWLINE_xXSteroids: Therapeutic doses of corticosteroids are prohibited within 7 days prior to leukapheresis.Xx_NEWLINE_xXOngoing immunosuppressive therapy other than corticosteroidsXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXParticipants must be receiving systemic corticosteroids. Treatment with methylprednisolone/systemic steroids must have been initiated within 72 hours prior to the first dose of study treatment after enrollmentXx_NEWLINE_xXThe use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.Xx_NEWLINE_xXActive treatment with corticosteroids or other immunosuppressive agentsXx_NEWLINE_xXCo-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids, such as systemic cyclosporine and tacrolimusXx_NEWLINE_xXChronic (treatment > 1 month) or ongoing treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXSubjects with any condition requiring systemic corticosteroids, cytotoxic therapy or immunosuppressive medicationsXx_NEWLINE_xXSubjects taking chronic systemic corticosteroid therapy for any reason are not eligible. Subjects may receive steroids as prophylactic anti-emetics per the mFOLFIRINOX regimen. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require chronic systemic corticosteroids after beginning treatment, will be removed from study.Xx_NEWLINE_xXUse of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to first dose of study treatment.Xx_NEWLINE_xXNo ongoing requirement for corticosteroidsXx_NEWLINE_xXPatients receiving chronic treatment with steroids or another immunosuppressive agent\r\n* Note: topical applications (eg, rash), inhaled sprays (eg, obstructive airways diseases), eye drops or local injections (eg, intr-articular) are allowed; oral or systemic liver enzyme inhibitors such as topical antifungal creams are allowed; patients with previously treated brain metastases, who are on stable low dose corticosteriods treatment (eg, dexamethasone 2 mg/day, prednisolone 10 mg/day) for at least 14 days before start of study treatment are eligibleXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXTreatment with an immunosuppressive regimen of corticosteroids or other immunosuppressive medication (e.g., methotrexate, rapamycin) within 30 days of study treatment; note: patients with adrenal insufficiency may take up to 5 mg of prednisone or equivalent daily; topical and inhaled corticosteroids in standard doses are allowedXx_NEWLINE_xXNo concurrent systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e. prednisone, dexamethasone), continuous use of topical steroid creams or ointments, or ophthalmologic steroids; if a subject is currently taking corticosteroids, treatment should be discontinued two weeks prior to starting protocol therapy; occasional use of steroid inhalers is allowedXx_NEWLINE_xXOngoing immunosuppressive therapy other than corticosteroidsXx_NEWLINE_xXuse of immunosuppressive therapy, including systemic steroids within 7 days before the first dose of SG2000.Xx_NEWLINE_xXPatients who require systemic corticosteroid or other systemic immunosuppressive therapy; immunosuppressive therapy must be stopped at least 28 days prior to enrollment; topical agents and/or inhaled corticosteroids are permittedXx_NEWLINE_xXCurrently receiving increasing or chronic treatment ( > 5 days) with corticosteroids (e.g. dexamethasone > 4 mg/day or other corticosteroids equivalent dose) or another immunosuppressive agent.Xx_NEWLINE_xXCurrent use of systemic steroid medicationXx_NEWLINE_xXDaily requirement for corticosteroids (except for inhalation corticosteroids).Xx_NEWLINE_xXIs receiving chronic corticosteroids administered at doses greater than those used for normal replacement therapyXx_NEWLINE_xXPatients requiring corticosteroids (other than inhaled) will be excludedXx_NEWLINE_xXSubjects who require pharmacologic doses of corticosteroids; replacement doses, topical, ophthalmologic, and inhalational steroids are permittedXx_NEWLINE_xXTreatment with systemic immunosuppressive medications within 2 weeks prior to the first dose of study treatment, or anticipated requirement for systemic immunosuppressive medications during the trialXx_NEWLINE_xXA requirement for daily systemic corticosteroids for any reason or a requirement for other immunosuppressive or immunomodulatory agents; topical, nasal, and inhaled steroids are permittedXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\r\n* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\r\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowedXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration should be excluded. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients are excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXPatients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medicationsXx_NEWLINE_xXA requirement for daily systemic corticosteroids for any reason or a requirement for other immunosuppressive or immunomodulatory agents; topical, nasal, and inhaled steroids are permittedXx_NEWLINE_xXChronic treatment with systemic steroids or another immunosuppressive agentXx_NEWLINE_xXImmunosuppressive treatment that cannot be discontinued both prior to study entry and for the duration of the study. Oral prednisone at a dose of 10 mg or less per day is allowed, as are other oral corticosteroids given at glucocorticoid-equivalent doses. Topical, nasal and inhaled corticosteroids are also allowedXx_NEWLINE_xXConcomitant therapy with any of the following: interleukin (IL) 2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses); however, during the course of the study, use of corticosteroids is allowed if used for treating immune-related adverse events (irAEs), adrenal insufficiencies, or if administered at doses of prednisone =< 10 mg daily or equivalentXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXDrugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen\r\n* Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXConcomitant therapy with any of the following: interleukin (IL)2 or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids; unless discontinued >= 4 weeks; a history of occasional use of steroid inhalers is allowedXx_NEWLINE_xXa short duration (< 5 days) of systemic corticosteroids e.g., of chronic obstructive pulmonary disease, or as an antiemetic corresponding at maximum to the anti-inflammatory potency of 4 mg dexamethasone for treatment;Xx_NEWLINE_xXRequirement for systemic chronic immunosuppressive drugs or systemic chronic corticosteroids for active autoimmune disorder(s) or other conditions (e.g.: rheumatoid arthritis, systemic lupus erythematous, multiple sclerosis, organ transplant recipient, etc.)Xx_NEWLINE_xXTreatment with oral/systemic corticosteroids =< 14 days prior to registration, with the exception of topical or inhaled steroids or steroids given for the purpose of antiemetics during chemotherapyXx_NEWLINE_xXActive immunosuppressive therapy associated with: Organ or allogeneic hematopoietic stem cell transplant, High-dose steroids, such as daily steroid doses in excess of 20 mg/day of prednisone (Note: Use of intra-articular or topical corticosteroids or eye drops containing corticosteroids is acceptable.), or Inhaled corticosteroids;Xx_NEWLINE_xXIs taking systemic corticosteroids (more than 3 consecutive days) or other immunomodulators or immune suppressive medicationXx_NEWLINE_xXPatients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatmentXx_NEWLINE_xXOngoing immunosuppressive therapy, including systemic corticosteroids. Patients may be using topical or inhaled corticosteroids.Xx_NEWLINE_xXPatients with a condition requiring systemic treatment with either corticosteroids (? 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.Xx_NEWLINE_xXPatients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids or steroid inhalersXx_NEWLINE_xXConcurrent use of systemic steroidsXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to, prednisone at doses > 10 mg [or equivalent dose of other corticosteroids], cyclophosphamide, tacrolimus, sirolimus, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to CDX-1401 administration (inhaled or topically applied steroids, and acute and chronic standard-dose nonsteroidal antiinflammatory drug [NSAID]s are permitted; replacement steroids are also permitted)Xx_NEWLINE_xXImmunosuppressive or systemic steroids medication within 7 days before the first dose of KTN3379 (inhaled and topical corticosteroids are permitted).Xx_NEWLINE_xXUse of immunosuppressive medication within 14 days before the first dose of mogamulizumab. Note: Inhaled, intranasal, intra-articular, or topical corticosteroids are allowed. Non-immunosuppresive doses of systemic steroids for adrenal replacement or for contrast allergy are allowed;;Xx_NEWLINE_xXCurrently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)Xx_NEWLINE_xXConcurrent use of corticosteroids (exception: nasal corticosteroids, inhaled steroids, adrenal replacement steroids and steroid creams are allowed)Xx_NEWLINE_xXHas any pre-existing medical condition requiring systemic chronic steroid or immunosuppressive therapy a) Inhaled corticosteroids for COPD or topical steroids are allowedXx_NEWLINE_xXConcurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical, nasal, or inhaled) steroid use; limited pharmacologic doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent intravenous [I.V.] contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowedXx_NEWLINE_xXUse of any systemic immunosuppressive agentsXx_NEWLINE_xXPatients who require treatment with systemic corticosteroids for serious medical conditions or illnesses (e.g. immunosuppression after organ transplantation)Xx_NEWLINE_xXNo concomitant therapy with any of the following: aldesleukin (IL2), interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids; all such therapies must have been discontinued >= 4 weeksXx_NEWLINE_xXAny concurrent medical condition requiring the use of systemic steroids is not permitted (the use of inhaled or topic steroids is permitted)Xx_NEWLINE_xXChronic steroid or immunosuppressive therapy (except for low dose corticosteroids for chronic obstructive pulmonary disease [COPD] or topical steroids, which are allowed)Xx_NEWLINE_xXUse of oral or intravenous corticosteroids or other immunosuppressive medications such as cyclosporine or azathioprine; subjects must not have received any systemic immunosuppressive drug such as corticosteroids for at least 2 weeks prior to study entry; maintenance inhaled corticosteroids for controlled asthma or chronic obstructive pulmonary disease (COPD) or maintenance systemic steroids to correct autoimmune endocrinopathy due to prior ipilimumab treatment is allowed as is the use of topical steroids and anti-inflammatory eye dropsXx_NEWLINE_xXSystemic immunosuppressive agents (including corticosteroids) have not been received for at least 8 weeksXx_NEWLINE_xXNo systemic or inhaled corticosteroids within 7 days prior to initiation of protocol therapy; NOTE: use of topical corticosteroids and/or eye drops containing glucocorticosteroids is acceptableXx_NEWLINE_xXPatients receiving unstable or increasing doses of corticosteroids. If patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms, dose must have been stabilized (or decreasing) for at least 5 days before first dose of study treatment.Xx_NEWLINE_xXCurrent, chronic treatment with steroids or another immunosuppressive agent\r\n* Note: topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are allowed; if a patient stops corticosteroids prior to study participation, a 2-week washout is requiredXx_NEWLINE_xXFixed or decreasing dose of corticosteroids (or no corticosteroids) >= 7 days prior to registrationXx_NEWLINE_xXInhaled, intranasal, intraarticular and topical steroids are permittedXx_NEWLINE_xXIncreasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agentXx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXImmunosuppressive medications or immunosuppressive doses of systemic corticosteroidsXx_NEWLINE_xXSystemic corticosteroids for any reason (inhaled corticosteroids are allowed)Xx_NEWLINE_xXPatients on corticosteroids for any reasonXx_NEWLINE_xXFor both Parts 1 and 2, receipt of HSCT within 60 days of the first dose of PLX3397 is an exclusion criterion. Patients on immunosuppressive therapy post HSCT, or with clinically significant graft-versus-host disease are excluded from Part 1. (Use of topical steroids for ongoing skin GVHD is permitted). Patients for Part 1 must have a wash-out period of ?2 weeks or at least 4 half-lives from their last systemic immunosuppressive treatment for GVHD. Patients for Part 2 may be receiving systemic immunosuppressive treatment for management of GVHD at the time of screening and enrollmentXx_NEWLINE_xXConcomitant therapy with any of the following: aldesleukin (IL-2), interferon, or other non-study immunotherapy regimens; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroidsXx_NEWLINE_xXPatients who have received systemic corticosteroids =< 2 weeks prior to starting study drug; systemic corticosteroids should not be administered with BKM120 (usage of steroids as premedications and anti-emetics for paclitaxel and carboplatin, per MSKCC guidelines, is allowed; steroids given as part of pre-medications for imaging studies are not exclusionary)Xx_NEWLINE_xXPatients taking systemic corticosteroidsXx_NEWLINE_xXPatients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids or steroid inhalers\r\n* If a patient had been taking steroids, at least 2 weeks must have passed since the last doseXx_NEWLINE_xXChronic treatment with systemic steroids or another immunosuppressive agentXx_NEWLINE_xXUse of immunosuppressive medication or systemic steroids within 7 days prior to first dose of MEDI3617Xx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; (topical or inhaled corticosteroids are allowed)Xx_NEWLINE_xXCorticosteroids discontinued ?7 days of initiating therapyXx_NEWLINE_xXThe patient requires concomitant chronic treatment (more than 7 consecutive days) with systemic corticosteroids or any other immunosuppressive agents.Xx_NEWLINE_xXPatients who require chronic daily oral corticosteroid or other immunosuppressive therapy; topical or inhaled corticosteroids are permitted;’ also, a time limited course of steroids for an unrelated medical condition (e.g. allergic reaction, poison ivy) will not preclude receipt of immunotherapy provided that two weeks elapse between the last dose of systemic corticosteroids and initiation of immunotherapyXx_NEWLINE_xXPatients who require chronic daily oral corticosteroid or other immunosuppressive therapy; topical or inhaled corticosteroids are permitted; also, a time limited course of steroids doses for an unrelated medical condition (e.g. allergic reaction, poison ivy) will not preclude receipt of immunotherapy provided that two weeks elapse between the last dose of systemic corticosteroids and initiation of immunotherapyXx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agentXx_NEWLINE_xXPatients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroidsXx_NEWLINE_xXSystemic steroid (except inhaled steroids) or other immunosuppressive therapy administered for more than 10 days within 4 weeks of enrollmentXx_NEWLINE_xXPatients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids, and treatment with low dose Decadron (=< 3 mg daily) are allowedXx_NEWLINE_xXUse of corticosteroids, thalidomide, bortezomib, or cytotoxic chemotherapy within 2 weeks of the first dose of elotuzumab except for steroids with little or no systemic absorption (ie, topical or inhaled steroids).Xx_NEWLINE_xXConcurrent treatment with systemic corticosteroids; local (inhaled or topical) steroids are permittedXx_NEWLINE_xXPrior corticosteroids allowedXx_NEWLINE_xXConcomitant medications\r\n** No systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days of registration (inhaled steroids for patients with underlying chronic pulmonary disease is acceptable as long as they meet other eligibility as listed above)\r\n** No other planned concurrent investigational agents or other tumor directed therapy (chemotherapy, radiation) while on studyXx_NEWLINE_xXSubjects with immunosuppressive disease that require use of systemic steroids or immunosuppressive treatmentXx_NEWLINE_xXHistory or evidence of active autoimmune disease, requiring systemic steroid therapy within 28 days of study screening or other systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) or anticipated requirement for systemic immunosuppressive medications during the trial\r\n* Patients on inhaled or topical steroids are eligible\r\n* Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the principal investigator\r\n* Replacement therapy (e.g., thyroxin, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatmentXx_NEWLINE_xXPresence of a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of study drug administration; Note: Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease the absence of active autoimmune diseaseXx_NEWLINE_xXConcurrent treatment with systemic corticosteroids (prednisone dose > 10 mg per day or equivalent) or other immunosuppressive drugs < 14 days prior to treatment initiation; steroids that are topical, inhaled, nasal (spray), or ophthalmic solution are permittedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid (steroids as pre-med for hypersensitivity reactions eg. computed tomography (CT) scan premedication is acceptable)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days of treatment on protocol, with the exception of intranasal and inhaled corticosteroids or oral corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroidXx_NEWLINE_xXPatients requiring corticosteroids (other than inhaled) will be excludedXx_NEWLINE_xXUnstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms (non-CNS), dose must have been stabilized (or decreasing) for at least 5 days before first dose of study treatment\r\n* Topical and inhaled steroids are allowedXx_NEWLINE_xXPatient is currently receiving increasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent, as chronic administration of corticosteroids (> 5 days) can induce cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)\r\n* The following uses of corticosteroids are permitted: single doses; e.g. with standard premedication for taxanes; topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g., intra-articular)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days prior to first study dose, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at doses not to exceed 10 mg/day of prednisone or equivalent. Steroids as premedication for hypersensitivity reactions due to radiographic contrast agents are allowed.Xx_NEWLINE_xXHas a history of a well-characterized and defined immune deficiency before the diagnosis of MF/SS or is receiving systemic steroid therapy greater than 10mg/day of prednisone or equivalent within 4 weeks or any other form of immunosuppressive therapy within 7 days before the first dose of trial treatment; the use of physiologic replacement doses of corticosteroids, along with topical, inhaled and local injection is discussedXx_NEWLINE_xXCorticosteroids or any other immunosuppressive therapy within 2 weeks. Use of inhaled or topical cutaneous steroids is permitted.Xx_NEWLINE_xXPatients must not require use of systemic corticosteroid within 14 days prior to registration or during protocol treatment; patients with preexisting severe autoimmune disease requiring systemic corticosteroids or ongoing immunosuppression are not eligibleXx_NEWLINE_xXThe use of immunosuppressive medication within 28 days prior to the first dose of durvalumab; the following are exceptions to this criterion:\r\n* Intranasal, topical, inhaled corticosteroids or local steroid injections (e.g. intraarticular injection)\r\n* Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication)Xx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 7 days prior to enrollment with the following exceptions to this exclusion criterion: \r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)Xx_NEWLINE_xXPatients must not be receiving any of the following concomitant medications:\r\n* Pharmacologic doses of systemic corticosteroids unless for CNS metastatic or primary disease; for patients with CNS metastatic or primary tumors receiving corticosteroids, they should be on a stable or decreasing dose over the 7 days prior to registration; for all patients, receipt of systemic physiologic replacement steroids, topical, and/or inhaled corticosteroids is acceptable\r\n* Non-steroidal anti-inflammatory drugs, oral anticoagulants, and therapeutic heparinsXx_NEWLINE_xXTreatment with systemic immunosuppressive medications including but not limited to: prednisone, dexamethasone, cyclosporin, azathioprine, methotrexate, thalidomide, anti-tumor necrosis factor (TNF) agents , hydroxychloroquine within 2 weeks of first study dose\r\n* Patients who have received acute, low-dose systemic immunosuppressant medications may be enrolled\r\n* Patients with adrenal insufficiency on physiologic replacement doses of steroids may be enrolled\r\n* The use of inhaled, topical intraocular, or intraarticular corticosteroids or mineralocorticoids are allowedXx_NEWLINE_xXConcurrent medical condition requiring the use of systemic immunosuppressive medications within 7 days before the first dose of study treatment. Physiologic doses of corticosteroids for treatment of endocrinopathies or steroids with minimal systemic absorption, including topical, inhaled, or intranasal corticosteroids may be continued if the subject is on a stable dose.Xx_NEWLINE_xXTreatment with high dose systemic corticosteroids or continuous use of other immunosuppressants within the past 30 daysXx_NEWLINE_xXPatient has received systemic corticosteroids or sedative antihistamines (dimenhydrinate, diphenhydramine, etc.) within 72 hours of day 1 of the study except as premedication for chemotherapy (e.g., taxanes); subjects who are receiving inhaled steroids for respiratory conditions or topical steroids for skin disorders can be enrolledXx_NEWLINE_xXCurrent use of corticosteroids defined as oral, intravenous (IV), or injections of corticosteroids in the past 4 weeks\r\n* If the patient is only prescribed a short-term, time-limited dose of oral, intravenous (IV), or injections of corticosteroids, then they may be rescreened for eligibility once they are >= 4 weeks post-completion of their course of corticosteroidsXx_NEWLINE_xXUse of oral corticosteroids or topical corticosteroids in the irradiation areaXx_NEWLINE_xXProlonged systemic corticosteroid treatment, except for topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airway diseases), eye drops, or local insertion (e.g., intra-articular)\r\n* Note: Short duration (< 2 weeks) of systemic corticosteroids is allowed (e.g., for chronic obstructive pulmonary disease), but not within 30 days prior to registrationXx_NEWLINE_xXSubjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first dose of study drug; inhaled or topical steroids, and adrenal replacement steroid doses are permitted in the absence of active autoimmune diseaseXx_NEWLINE_xXPatients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drugXx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedXx_NEWLINE_xXFor Arms L (pembrolizumab) and M (nivolumab), subjects receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or other form of immunosuppressive therapy within 7 days before the first dose of study treatment; use of inhaled or topical steroids or systemic corticosteroidsXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXPatients on chronic immunosuppressive medications, including steroids, within the past three monthsXx_NEWLINE_xXParticipants may not have received > 1 systemic immunosuppressive agent beyond corticosteroids for the treatment of GVHD; GVHD prophylaxis regimens used for an individual patient do not count as additional agentsXx_NEWLINE_xXPatients must not have received oral corticosteroids, intramuscular corticosteroids, or intra-articular steroids for joint symptoms within 28 days prior to registrationXx_NEWLINE_xXUse of any systemic oral or parenteral steroid containing medications is not permitted; use of “High Daily Dose” inhaled/intranasal corticosteroids is not permitted; use inhaled/intranasal corticosteroid preparations at dosing levels less than “High Daily Dose” is permittedXx_NEWLINE_xXNo concurrent use of chronic systemic steroids (defined as currently on more than 1 week of treatment)Xx_NEWLINE_xXStable dose of corticosteroids for treatment of GVHD for 2 weeks prior to enrollment (fluctuation of corticosteroids for treatment of anything other than GVHD acceptable)Xx_NEWLINE_xXTreatment with high dose systemic corticosteroids or continuous use of other immunosuppressants within the past 6 monthsXx_NEWLINE_xXPatients on chronic corticosteroidsXx_NEWLINE_xXAutoimmune disorders, transplant recipients, other immunosuppression including any concurrent condition requiring the use of immunosuppressive/ immunomodulating agents; Exception: eye drop-containing and infrequent inhaled corticosteroids are permissible; topical corticosteroids are permissible at locations other than the administration site (upper arm); Note: All systemic corticosteroids must be discontinued at least 4 weeks prior to randomization; inhaled corticosteroids must be discontinued >= 48 hours prior to randomization and courses of more than 2 weeks are not permissible within 4 weeks of randomizationXx_NEWLINE_xXReceiving immunosuppressive therapy including chronic steroids, methotrexate, or other known immunosuppressive agentsXx_NEWLINE_xXPatients on chronic steroid therapy or other immunosuppressive therapy except for topical or inhaled steroids known to have low systemic absorptionXx_NEWLINE_xXUse of oral or systemic steroids or other anti?immune therapy =< 90 days prior to pre?registration; Note: Use of inhaled/nasal steroids is not exclusionaryXx_NEWLINE_xXHistory of severe asthma and currently on chronic systemic medications (mild asthma requiring inhaled steroids only is eligible)Xx_NEWLINE_xXPatients with steroid refractory chronic GVHD must be on stable doses of corticosteroids and other immunosuppressive medications for 2 weeks prior to enrollmentXx_NEWLINE_xXRecent (within 4 weeks of screening) or concomitant long term treatment with systemic steroids, immunosuppressive/immunomodulating drugs (e.g. cyclosporine, corticosteroids)\r\n* Intranasal, inhaled and/or topical steroids are permissibleXx_NEWLINE_xXOther risk factors for the development of osteonecrosis of the jaw (ONJ) including poor oral hygiene, use of a dental appliance, immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, or gingival infectionsXx_NEWLINE_xXPatients on systemic corticosteroids (oral or intravenous)Xx_NEWLINE_xXChronic administration (defined as daily or every other day for continued use > 14 days) of systemic corticosteroids within 28 days of the first planned dose of PROSTVAC-V/F; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowedXx_NEWLINE_xX2. Any concurrent condition requiring the continued or anticipated use of systemic steroids (excluding non-systemic inhaled, topical skin and/or eye drop-containing corticosteroids) or immunosuppressive therapy (excludes low dose methotrexate). All other systemic corticosteroids must be discontinued at least 4 weeks prior to first Study Treatment;Xx_NEWLINE_xXSkin conditions that require consistent use of topical corticosteroids or other local or systemic therapy that may interfere with interpretation or description of skin-related adverse events linked to vaccinationXx_NEWLINE_xXTreatment with systemic immunosuppressive medications within 2 weeks prior to first day of study treatment (inhaled corticosteroids and mineralocorticoids allowed)Xx_NEWLINE_xXChronic administration of immunosuppressive agents or other immune-modifying drugs or chemotherapeutic agents within six months prior to the first vaccine dose; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowedXx_NEWLINE_xXImmunosuppressive treatment that cannot be discontinued both prior to study entry and for the duration of the study. Oral prednisone at a dose of 10 mg or less per day is allowed, as are other oral corticosteroids given at glucocorticoid-equivalent doses. Topical, nasal and inhaled corticosteroids are also allowedXx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowedXx_NEWLINE_xXTreatment with systemic immunosuppressive medicationXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications including but not limited to: prednisone, dexamethasone, cyclosporine, azathioprine, methotrexate, thalidomide, antitumor necrosis factor (TNF) agents within 2 weeks of first study dose\r\n* Subjects who have received acute, low-dose systemic immunosuppressant medications may be enrolled (such as steroids for acute nausea or cancer-related pain =< 10 mg prednisone) maybe enrolled sooner than 2 weeks of first study dose\r\n* Subjects with adrenal insufficiency on physiologic replacement doses of steroids may be enrolled (=< 10 mg prednisone)\r\n* The use of inhaled, topical, ocular or intra-articular corticosteroids and mineralocorticoids are allowedXx_NEWLINE_xXTherapeutic doses of corticosteroids within 7 days of leukapheresis or 72 hours prior to JCAR017 administration. Physiologic replacement, topical, inhaled, and intranasal steroids are permitted.Xx_NEWLINE_xXChronic treatment with corticosteroids or other immunosuppressive agents. Topical or inhaled corticosteroids are allowed;Xx_NEWLINE_xXSubject is currently using or has used immunosuppressive medication within 14 days prior to the study agent administration; the following are exceptions:\r\n* Intranasal, topical, inhaled, or local steroid injections (e.g., intra-articular injection)\r\n* Chronic systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., infusion-related reactions, CT scan premedication)Xx_NEWLINE_xXImmunosuppressive therapy including systemic corticosteroids except for maintenance dosing for adrenal insufficiencyXx_NEWLINE_xXIntranasal, inhaled, topical, intra-articular, and ocular corticosteroids with minimal systemic absorption are permitted.Xx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressant medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti?tumor necrosis factor [TNF] agents) within 2 weeks prior to cycle 1, day 1, or anticipated requirement for systemic immunosuppressive medications during the trial; patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study; patients with a history of allergic reaction to IV contrast requiring steroid pre-treatment should have baseline and subsequent tumor assessments performed using magnetic resonance imaging (MRI); the use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowedXx_NEWLINE_xXCurrent or prior use of immunosuppressive medication within 14 days prior to first vaccine; the following are exceptions to this criterion: intranasal, inhaled, topical or local steroid injections (e.g. intra-articular injection); steroids as premedication for hypersensitivity reactions; systemic corticosteroid at physiologic doses not to exceed 10 mg/day of prednisone or equivalentXx_NEWLINE_xXCurrent use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)Xx_NEWLINE_xXPatients with evidence of significant intracranial mass effect that requires > 4 mg of dexamethasone or bioequivalent per day for 5 consecutive days for management of symptoms at any time within 14 days of registration\r\n* Subjects on a standard high-dose steroid taper after craniotomy may receive a higher dose of corticosteroids within 14 days of registration, however must be at a dose =< 4 mg of dexamethasone or bioequivalent per day within 5 days prior to registration\r\n* Administration of steroids through a route known to result in a minimal systemic exposure (i.e., intranasal, intraocular, inhaled, topical, or local injection [e.g., intra-articular injection] corticosteroids [< 5% of body surface area]) are permitted\r\n* Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are at doses =< 10 mg prednisone or bioequivalent per day\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) are allowedXx_NEWLINE_xXClinical requirement for systemic corticosteroids for control of cerebral edema or for enzyme-inducing anticonvulsants; (inhaled steroids and systemic steroids for chronic obstructive pulmonary disease [COPD] are permitted)Xx_NEWLINE_xXTreatment within 3 months with immunomodulatory therapy (e.g., interferons, immunoglobulin therapy, interleukin 1 receptor antagonist or systemic corticosteroids); short-term systemic corticosteroids or topical or intra-articular steroids are acceptable, at the discretion of the InvestigatorXx_NEWLINE_xXCurrent or prior systemic use of corticosteroids in the past monthXx_NEWLINE_xXPatients on chronic therapy with any systemic immunosuppressant (not counting inhaled steroids or steroid creams) for any reason, including autoimmune diseaseXx_NEWLINE_xXUse of topical or systemic agents/treatments for OM within 2 weeks of treatment day 1.Xx_NEWLINE_xXCorticosteroids: no restrictionsXx_NEWLINE_xXHas a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration.Xx_NEWLINE_xXPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen), or as pre-phase treatment for cytoreduction; patients will receive steroids with blinatumomab to reduce cytokine release syndrome (CRS) as specified in the protocolXx_NEWLINE_xXSubjects on systemic immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). The use of topical steroids for ongoing skin or ocular GVHD is permitted.Xx_NEWLINE_xXAny condition requiring systemic treatment with corticosteroids (less than [>]10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 before first dose of study drug. o Corticosteroids for topical use or in nasal spray are allowed, as are inhaled steroids and adrenal replacement steroid doses >10 mg daily in the absence of active autoimmune disease.Xx_NEWLINE_xXTreatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to Cycle 1, Day 1 or anticipated requirement for systemic immunosuppressive medications during the studyXx_NEWLINE_xXcurrently or previously required systemic immunosuppressive or immunomodulatory therapy (including corticosteroids administered by systemic route) and/orXx_NEWLINE_xXSystemic treatment with steroids or other immunosuppressive agents within 30 days prior to entry. Physiological replacement with hydrocortisone or equivalent is acceptable.Xx_NEWLINE_xX